A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).
A severe sometimes chronic anemia, usually macrocytic in type, that does not respond to ordinary antianemic therapy.
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)
Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.
Anemia characterized by a decrease in the ratio of the weight of hemoglobin to the volume of the erythrocyte, i.e., the mean corpuscular hemoglobin concentration is less than normal. The individual cells contain less hemoglobin than they could have under optimal conditions. Hypochromic anemia may be caused by iron deficiency from a low iron intake, diminished iron absorption, or excessive iron loss. It can also be caused by infections or other diseases, therapeutic drugs, lead poisoning, and other conditions. (Stedman, 25th ed; from Miale, Laboratory Medicine: Hematology, 6th ed, p393)
Anemia characterized by larger than normal erythrocytes, increased mean corpuscular volume (MCV) and increased mean corpuscular hemoglobin (MCH).
A megaloblastic anemia occurring in children but more commonly in later life, characterized by histamine-fast achlorhydria, in which the laboratory and clinical manifestations are based on malabsorption of vitamin B 12 due to a failure of the gastric mucosa to secrete adequate and potent intrinsic factor. (Dorland, 27th ed)
Anemia characterized by the presence of erythroblasts containing excessive deposits of iron in the marrow.
A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.
Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
The period of time following the triggering of an ACTION POTENTIAL when the CELL MEMBRANE has changed to an unexcitable state and is gradually restored to the resting (excitable) state. During the absolute refractory period no other stimulus can trigger a response. This is followed by the relative refractory period during which the cell gradually becomes more excitable and the stronger impulse that is required to illicit a response gradually lessens to that required during the resting state.
A disorder characterized by the presence of ANEMIA, abnormally large red blood cells (megalocytes or macrocytes), and MEGALOBLASTS.
The oxygen-carrying proteins of ERYTHROCYTES. They are found in all vertebrates and some invertebrates. The number of globin subunits in the hemoglobin quaternary structure differs between species. Structures range from monomeric to a variety of multimeric arrangements.
A species of LENTIVIRUS, subgenus equine lentiviruses (LENTIVIRUSES, EQUINE), causing acute and chronic infection in horses. It is transmitted mechanically by biting flies, mosquitoes, and midges, and iatrogenically through unsterilized equipment. Chronic infection often consists of acute episodes with remissions.
Hemolytic anemia due to various intrinsic defects of the erythrocyte.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
Viral disease of horses caused by the equine infectious anemia virus (EIAV; INFECTIOUS ANEMIA VIRUS, EQUINE). It is characterized by intermittent fever, weakness, and anemia. Chronic infection consists of acute episodes with remissions.
The type species of GYROVIRUS, a small, non-enveloped DNA virus originally isolated from contaminated vaccines in Japan. It causes chicken infectious anemia and may possibly play a key role in hemorrhagic anemia syndrome, anemia dermatitis, and blue wing disease.
A familial disorder characterized by ANEMIA with multinuclear ERYTHROBLASTS, karyorrhexis, asynchrony of nuclear and cytoplasmic maturation, and various nuclear abnormalities of bone marrow erythrocyte precursors (ERYTHROID PRECURSOR CELLS). Type II is the most common of the 3 types; it is often referred to as HEMPAS, based on the Hereditary Erythroblast Multinuclearity with Positive Acidified Serum test.
A rare congenital hypoplastic anemia that usually presents early in infancy. The disease is characterized by a moderate to severe macrocytic anemia, occasional neutropenia or thrombocytosis, a normocellular bone marrow with erythroid hypoplasia, and an increased risk of developing leukemia. (Curr Opin Hematol 2000 Mar;7(2):85-94)
A diverse group of proteins whose genetic MUTATIONS have been associated with the chromosomal instability syndrome FANCONI ANEMIA. Many of these proteins play important roles in protecting CELLS against OXIDATIVE STRESS.
A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
The return of a sign, symptom, or disease after a remission.
The co-occurrence of pregnancy and a blood disease (HEMATOLOGIC DISEASES) which involves BLOOD CELLS or COAGULATION FACTORS. The hematologic disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS.
The mildest form of erythroblastosis fetalis in which anemia is the chief manifestation.
Agents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value.
A Fanconi anemia complementation group protein that regulates the activities of CYTOCHROME P450 REDUCTASE and GLUTATHIONE S-TRANSFERASE. It is found predominately in the CYTOPLASM, but moves to the CELL NUCLEUS in response to FANCE PROTEIN.
A Fanconi anemia complementation group protein that undergoes mono-ubiquitination by FANCL PROTEIN in response to DNA DAMAGE. Also, in response to IONIZING RADIATION it can undergo PHOSPHORYLATION by ataxia telangiectasia mutated protein. Modified FANCD2 interacts with BRCA2 PROTEIN in a stable complex with CHROMATIN, and it is involved in DNA REPAIR by homologous RECOMBINATION.
A Fanconi anemia complementation group protein that is the most commonly mutated protein in FANCONI ANEMIA. It undergoes PHOSPHORYLATION by PROTEIN KINASE B and forms a complex with FANCC PROTEIN in the CELL NUCLEUS.
The production of red blood cells (ERYTHROCYTES). In humans, erythrocytes are produced by the YOLK SAC in the first trimester; by the liver in the second trimester; by the BONE MARROW in the third trimester and after birth. In normal individuals, the erythrocyte count in the peripheral blood remains relatively constant implying a balance between the rate of erythrocyte production and rate of destruction.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Iron-containing proteins that are widely distributed in animals, plants, and microorganisms. Their major function is to store IRON in a nontoxic bioavailable form. Each ferritin molecule consists of ferric iron in a hollow protein shell (APOFERRITINS) made of 24 subunits of various sequences depending on the species and tissue types.
Any one of a group of congenital hemolytic anemias in which there is no abnormal hemoglobin or spherocytosis and in which there is a defect of glycolysis in the erythrocyte. Common causes include deficiencies in GLUCOSE-6-PHOSPHATE ISOMERASE; PYRUVATE KINASE; and GLUCOSE-6-PHOSPHATE DEHYDROGENASE.
A clinical manifestation consisting of an unnatural paleness of the skin.
The number of RED BLOOD CELLS per unit volume in a sample of venous BLOOD.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
ERYTHROCYTE size and HEMOGLOBIN content or concentration, usually derived from ERYTHROCYTE COUNT; BLOOD hemoglobin concentration; and HEMATOCRIT. The indices include the mean corpuscular volume (MCV), the mean corpuscular hemoglobin (MCH), and the mean corpuscular hemoglobin concentration (MCHC).
The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed)
Measurement of hemoglobin concentration in blood.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Antibodies obtained from a single clone of cells grown in mice or rats.
Therapeutic act or process that initiates a response to a complete or partial remission level.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN.
A subnormal level of BLOOD PLATELETS.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Elements of limited time intervals, contributing to particular results or situations.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
A Fanconi anemia complementation group protein that undergoes PHOSPHORYLATION by CDC2 PROTEIN KINASE during MITOSIS. It forms a complex with other FANCONI ANEMIA PROTEINS and helps protect CELLS from DNA DAMAGE by genotoxic agents.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
A test to detect non-agglutinating ANTIBODIES against ERYTHROCYTES by use of anti-antibodies (the Coombs' reagent.) The direct test is applied to freshly drawn blood to detect antibody bound to circulating red cells. The indirect test is applied to serum to detect the presence of antibodies that can bind to red blood cells.
The number of RETICULOCYTES per unit volume of BLOOD. The values are expressed as a percentage of the ERYTHROCYTE COUNT or in the form of an index ("corrected reticulocyte index"), which attempts to account for the number of circulating erythrocytes.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
Iron or iron compounds used in foods or as food. Dietary iron is important in oxygen transport and the synthesis of the iron-porphyrin proteins hemoglobin, myoglobin, cytochromes, and cytochrome oxidase. Insufficient amounts of dietary iron can lead to iron-deficiency anemia.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
Antibodies produced by a single clone of cells.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Drugs used to prevent SEIZURES or reduce their severity.
Therapy with two or more separate preparations given for a combined effect.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Organic and inorganic compounds that contain iron as an integral part of the molecule.
Forms of hepcidin, a cationic amphipathic peptide synthesized in the liver as a prepropeptide which is first processed into prohepcidin and then into the biologically active hepcidin forms, including in human the 20-, 22-, and 25-amino acid residue peptide forms. Hepcidin acts as a homeostatic regulators of iron metabolism and also possesses antimicrobial activity.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Oxygen-carrying RED BLOOD CELLS in mammalian blood that are abnormal in structure or function.
Inorganic or organic compounds that contain the basic structure RB(OH)2.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
The transfer of erythrocytes from a donor to a recipient or reinfusion to the donor.
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
A delayed response interval occurring when two stimuli are presented in close succession.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
A nutritional condition produced by a deficiency of VITAMIN B 12 in the diet, characterized by megaloblastic anemia. Since vitamin B 12 is not present in plants, humans have obtained their supply from animal products, from multivitamin supplements in the form of pills, and as additives to food preparations. A wide variety of neuropsychiatric abnormalities is also seen in vitamin B 12 deficiency and appears to be due to an undefined defect involving myelin synthesis. (From Cecil Textbook of Medicine, 19th ed, p848)
Proteins prepared by recombinant DNA technology.
The senescence of RED BLOOD CELLS. Lacking the organelles that make protein synthesis possible, the mature erythrocyte is incapable of self-repair, reproduction, and carrying out certain functions performed by other cells. This limits the average life span of an erythrocyte to 120 days.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
Transplantation of an individual's own tissue from one site to another site.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Disorders of the blood and blood forming tissues.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
A genus in the family ORTHOMYXOVIRIDAE containing one species: Infectious salmon anemia virus.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
The giving of drugs, chemicals, or other substances by mouth.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.
Surgical procedure involving either partial or entire removal of the spleen.
Persistent pain that is refractory to some or all forms of treatment.
Nucleosides containing arabinose as their sugar moiety.
A decrease in the number of NEUTROPHILS found in the blood.
A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.
Enlargement of the spleen.
A Fanconi anemia complementation group protein. It is an essential component of a nuclear core complex that protects the GENOME against CHROMOSOMAL INSTABILITY. It interacts directly with FANCG PROTEIN and helps stabilize a complex with FANCA PROTEIN and FANCC PROTEIN.
Diazo derivatives of aniline, used as a reagent for sugars, ketones, and aldehydes. (Dorland, 28th ed)
A Fanconi anemia complementation group protein that interacts with FANCC PROTEIN and FANCD2 PROTEIN. It promotes the accumulation of FANCC protein in the CELL NUCLEUS.
The major component of hemoglobin in the fetus. This HEMOGLOBIN has two alpha and two gamma polypeptide subunits in comparison to normal adult hemoglobin, which has two alpha and two beta polypeptide subunits. Fetal hemoglobin concentrations can be elevated (usually above 0.5%) in children and adults affected by LEUKEMIA and several types of ANEMIA.
Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely. (From Adams et al., Principles of Neurology, 6th ed, pp317)
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
An impulse-conducting system composed of modified cardiac muscle, having the power of spontaneous rhythmicity and conduction more highly developed than the rest of the heart.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
Increased numbers of platelets in the peripheral blood. (Dorland, 27th ed)
A compound suggested to be both a nootropic and a neuroprotective agent.
A nutritional condition produced by a deficiency of FOLIC ACID in the diet. Many plant and animal tissues contain folic acid, abundant in green leafy vegetables, yeast, liver, and mushrooms but destroyed by long-term cooking. Alcohol interferes with its intermediate metabolism and absorption. Folic acid deficiency may develop in long-term anticonvulsant therapy or with use of oral contraceptives. This deficiency causes anemia, macrocytic anemia, and megaloblastic anemia. It is indistinguishable from vitamin B 12 deficiency in peripheral blood and bone marrow findings, but the neurologic lesions seen in B 12 deficiency do not occur. (Merck Manual, 16th ed)
Disease having a short and relatively severe course.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.
A cobalt-containing coordination compound produced by intestinal micro-organisms and found also in soil and water. Higher plants do not concentrate vitamin B 12 from the soil and so are a poor source of the substance as compared with animal tissues. INTRINSIC FACTOR is important for the assimilation of vitamin B 12.
Large, hoofed mammals of the family EQUIDAE. Horses are active day and night with most of the day spent seeking and consuming food. Feeding peaks occur in the early morning and late afternoon, and there are several daily periods of rest.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
An infant during the first month after birth.
Accumulation or retention of free fluid within the peritoneal cavity.
The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.
A small nodular mass of specialized muscle fibers located in the interatrial septum near the opening of the coronary sinus. It gives rise to the atrioventricular bundle of the conduction system of the heart.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
Immature, nucleated ERYTHROCYTES occupying the stage of ERYTHROPOIESIS that follows formation of ERYTHROID PRECURSOR CELLS and precedes formation of RETICULOCYTES. The normal series is called normoblasts. Cells called MEGALOBLASTS are a pathologic series of erythroblasts.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
Membrane glycoproteins found in high concentrations on iron-utilizing cells. They specifically bind iron-bearing transferrin, are endocytosed with its ligand and then returned to the cell surface where transferrin without its iron is released.
RED BLOOD CELL sensitivity to change in OSMOTIC PRESSURE. When exposed to a hypotonic concentration of sodium in a solution, red cells take in more water, swell until the capacity of the cell membrane is exceeded, and burst.
Immature ERYTHROCYTES. In humans, these are ERYTHROID CELLS that have just undergone extrusion of their CELL NUCLEUS. They still contain some organelles that gradually decrease in number as the cells mature. RIBOSOMES are last to disappear. Certain staining techniques cause components of the ribosomes to precipitate into characteristic "reticulum" (not the same as the ENDOPLASMIC RETICULUM), hence the name reticulocytes.
Regulation of the rate of contraction of the heart muscles by an artificial pacemaker.
A group of alkylating agents derived from mustard gas, with the sulfur replaced by nitrogen. They were formerly used as toxicants and vesicants, but now function as antineoplastic agents. These compounds are also powerful mutagens, teratogens, immunosuppressants, and carcinogens.
The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
Inorganic or organic compounds that contain divalent iron.
An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)
Abnormal intracellular inclusions, composed of denatured hemoglobin, found on the membrane of red blood cells. They are seen in thalassemias, enzymopathies, hemoglobinopathies, and after splenectomy.
Infection of humans or animals with hookworms other than those caused by the genus Ancylostoma or Necator, for which the specific terms ANCYLOSTOMIASIS and NECATORIASIS are available.
A group of inherited disorders characterized by structural alterations within the hemoglobin molecule.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
The cells in the erythroid series derived from MYELOID PROGENITOR CELLS or from the bi-potential MEGAKARYOCYTE-ERYTHROID PROGENITOR CELLS which eventually give rise to mature RED BLOOD CELLS. The erythroid progenitor cells develop in two phases: erythroid burst-forming units (BFU-E) followed by erythroid colony-forming units (CFU-E); BFU-E differentiate into CFU-E on stimulation by ERYTHROPOIETIN, and then further differentiate into ERYTHROBLASTS when stimulated by other factors.
An adjunctive treatment for PARTIAL EPILEPSY and refractory DEPRESSION that delivers electrical impulses to the brain via the VAGUS NERVE. A battery implanted under the skin supplies the energy.
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
A PREDNISOLONE derivative with similar anti-inflammatory action.
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
An anti-inflammatory 9-fluoro-glucocorticoid.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
An abnormal hemoglobin resulting from the substitution of valine for glutamic acid at position 6 of the beta chain of the globin moiety. The heterozygous state results in sickle cell trait, the homozygous in sickle cell anemia.
A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30)
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.
A glycoprotein secreted by the cells of the GASTRIC GLANDS that is required for the absorption of VITAMIN B 12 (cyanocobalamin). Deficiency of intrinsic factor leads to VITAMIN B 12 DEFICIENCY and ANEMIA, PERNICIOUS.
A disorder characterized by reduced synthesis of the alpha chains of hemoglobin. The severity of this condition can vary from mild anemia to death, depending on the number of genes deleted.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
The chambers of the heart, to which the BLOOD returns from the circulation.
Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY.
A group of familial congenital hemolytic anemias characterized by numerous abnormally shaped erythrocytes which are generally spheroidal. The erythrocytes have increased osmotic fragility and are abnormally permeable to sodium ions.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
The process by which fetal Rh+ erythrocytes enter the circulation of an Rh- mother, causing her to produce IMMUNOGLOBULIN G antibodies, which can cross the placenta and destroy the erythrocytes of Rh+ fetuses. Rh isoimmunization can also be caused by BLOOD TRANSFUSION with mismatched blood.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION.
An anthracenedione-derived antineoplastic agent.
Small cationic peptides that are an important component, in most species, of early innate and induced defenses against invading microbes. In animals they are found on mucosal surfaces, within phagocytic granules, and on the surface of the body. They are also found in insects and plants. Among others, this group includes the DEFENSINS, protegrins, tachyplesins, and thionins. They displace DIVALENT CATIONS from phosphate groups of MEMBRANE LIPIDS leading to disruption of the membrane.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
A condition characterized by the recurrence of HEMOGLOBINURIA caused by intravascular HEMOLYSIS. In cases occurring upon cold exposure (paroxysmal cold hemoglobinuria), usually after infections, there is a circulating antibody which is also a cold hemolysin. In cases occurring during or after sleep (paroxysmal nocturnal hemoglobinuria), the clonal hematopoietic stem cells exhibit a global deficiency of cell membrane proteins.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.
A republic in eastern Africa, south of UGANDA and north of MOZAMBIQUE. Its capital is Dar es Salaam. It was formed in 1964 by a merger of the countries of TANGANYIKA and ZANZIBAR.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
The co-occurrence of pregnancy and parasitic diseases. The parasitic infection may precede or follow FERTILIZATION.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions.
The type species of ERYTHROVIRUS and the etiological agent of ERYTHEMA INFECTIOSUM, a disease most commonly seen in school-age children.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
A member of the vitamin B family that stimulates the hematopoietic system. It is present in the liver and kidney and is found in mushrooms, spinach, yeast, green leaves, and grasses (POACEAE). Folic acid is used in the treatment and prevention of folate deficiencies and megaloblastic anemia.
Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.
A characteristic symptom complex.
The persistent eating of nonnutritive substances for a period of at least one month. (DSM-IV)

Analysis of the characteristics of folate binding proteins and its relationship with expression of multidrug resistance P-glycoprotein in myelodysplastic syndromes. (1/99)

OBJECTIVE: To observe the characteristics of folate binding proteins (FBP) in myelodysplastic syndromes (MDS) and leukemia and to study the clinical significance of reduced folate carrier (RFC) present in MDS and its relationship with multidrug resistance (MDR). METHODS: The features of FBP on bone marrow cells were analyzed using radiolabeled 3H-folic acid (3H-FA) binding membrane proteins and SDS-polyacrylamide gel electrophoresis (SDS-PAGE). In the same time, P-glucoprotein and mRNA of MDR gene were detected using immunocytochemistry and reverse transcription polymerase chain reaction (RT-PCR) respectively in patients with MDS and leukemia. RESULTS: Two kinds of FBP, folate receptor (FR) and reduced folate carrier (RFC), were found on the leukemic cells. The same results were presented on mononuclear cells of bone marrow in 5 out of 14 MDS patients, and MDR positive was seen in 4 patiens of them. In normal control and other 9 cases of MDS FRs were only found on the mononuclear cells of bone marrow. CONCLUSION: Reduced folate carrier, which is present in the leukemic cell, is a product of neoplastic cell. It might reveal preleukmic state and have the same significance with MDR that RFC is found in MDS patients.  (+info)

Prognostic significance of magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes. (2/99)

PURPOSE: To investigate whether the abnormalities observed on femoral marrow magnetic resonance images are related to the development of leukemia and survival of patients with myelodysplastic syndromes (MDS). PATIENTS AND METHODS: The findings on magnetic resonance images of the femoral marrow were evaluated over periods of 1 to 92 months (median, 18 months) in 42 consecutive adult patients with newly diagnosed MDS. Magnetic resonance images were obtained by the T1-weighted spin echo method and the short T1 inversion recovery technique. RESULTS: Magnetic resonance images showed that the femoral marrow patterns changed from fatty, faint, or nodular to scattered or uniform as the disease progressed. Development of acute myeloid leukemia was observed in only 13 patients whose marrow exhibited a scattered or uniform pattern. The overall survival of the 29 patients with a scattered or uniform marrow pattern was significantly shorter than that of the 13 patients with a fatty, faint, or nodular marrow pattern (10.7% v 73.3% at 7 years; P < .01). The period of leukemia-free survival was also significantly shorter in the patients with a scattered or uniform marrow pattern versus a fatty, faint, or nodular pattern (37.7% v 100% at 7 years; P < .01). CONCLUSION: Magnetic resonance images of the femoral marrow can provide valuable information for assessing the prognosis and determining the most appropriate management of patients with MDS.  (+info)

Two cases of myeloid disorders and a t(8;12) (q12;p13). (3/99)

BACKGROUND AND OBJECTIVE: Rearrangements of the short arm of chromosome 12 have been described in different hematologic malignancies. Some of these abnormalities showed a rearrangement of the ETV6 gene. We studied the 12p region in one case with a t(8;12)(q12;p13) by fluorescence in situ hybridization (FISH). DESIGN AND METHODS: We have identified a chromosome translocation, t(8;12)(q12;p13) in two patients with myeloid disorders; one with acute myelogenous leukemia (AML) and one with refractory anemia (RA). FISH studies with specific probes (cosmids and YACs) for the 12p region were used to investigate one case. RESULTS: FISH studies demonstrated hemizygous loss of the ETV6 and CDKN1B regions and two copies of the CCDN2 locus, as a result of the balanced translocation and an additional copy of the der(8). INTERPRETATION AND CONCLUSIONS: Myeloid diseases with t(8;12)(q12;p13) have an interstitial deletion of 12p, including the ETV6 and CDKN1B regions. A duplication of CCDN2 locus can also be found.  (+info)

Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. (4/99)

BACKGROUND AND OBJECTIVE: Lymphocyte abnormalities in myelodysplastic syndromes (MDS) have been widely described, but the role of the immune system in the pathogenesis of these clonal disorders remains controversial. An active role of lymphocytes in suppressing normal hematopoiesis may be implicated in MDS with hypoplastic marrow. We have studied in vitro and in vivo activity of cyclosporin-A (CSA) on hematopoiesis in patients affected by hypoplastic MDS without blast excess. DESIGN AND METHODS: Nine consecutive patients with hypoplastic refractory anemia (RA), followed up in our out-patient unit, were treated with CSA at daily doses of 1-3 mg/kg for at least three months. Low dose steroids or danazol were transiently added in 7/9 patients. Differences between pre- and post-treatment parameters were studied by the Student's t-test. In vitro effect of CSA on circulating hematopoietic progenitors was studied by the methylcellulose colony assay. RESULTS: Before treatment, fewer circulating hematopoietic progenitors were found in all patients as compared to normal subjects. The number of CD34+ cells was about halved, while circulating erythroid and myeloid colony-forming cells (CFC) were reduced to one-fifth. After a mean period of 22 months of CSA treatment (median: 14.5 months), hemoglobin was significantly and persistently increased in two patients, platelets in one, platelets and hemoglobin in two. Two patients showed transient responses, one patient did not tolerate the treatment and one patient is close to a significant response. At in vitro CSA concentrations similar to those achieved in vivo after oral administration the drug significantly increased cell colony growth in hypoplastic RA. This test correctly predicted a positive clinical response to CSA in 3/5 cases and treatment failure in 4/4 cases. INTERPRETATION AND CONCLUSIONS: About one half of hypoplastic RA patients benefited from CSA treatment. A larger study could verify whether in vitro culture of hematopoietic progenitors in the presence of CSA can predict the clinical response and whether this treatment could prolong patients' survival.  (+info)

Pseudo-Gaucher cells in myelodysplasia. (5/99)

A case of myelodysplastic syndrome is reported, in which the bone marrow contained many cells with the typical light microscopic morphology of Gaucher cells. In the absence of any evidence of inherited Gaucher's disease, these cells are considered to be pseudo-Gaucher cells, which have been described previously in association with other haematological diseases. This is the first report of their occurrence in myelodysplastic syndrome.  (+info)

Successful allogeneic bone marrow transplantation for childhood-onset refractory anemia with ringed sideroblasts. (6/99)

Refractory anemia with ringed sideroblasts (RARS) is an extremely rare type of myelodysplastic syndrome in children. We describe a 10-year-old boy with RARS presented with pancytopenia. He remained relatively stable with only a few transfusions until age of 20 years, when he underwent an allogeneic bone marrow transplantation (BMT) because of increased transfusion requirements. He remains in complete chimeric state at 20 months posttransplant with normal hematologic parameters. To our knowledge, this is the first description of successful BMT in a patient with childhood-onset RARS. The indication of BMT for this rare disorder in children is discussed.  (+info)

Detection of TNFalpha expression in the bone marrow and determination of TNFalpha production of peripheral blood mononuclear cells in myelodysplastic syndrome. (7/99)

TNFalpha is a highly active cytokine which plays an important role in the regulation of apoptotic cell death, a mechanism involved in the pathophysiology of myelodysplastic syndrome (MDS). In this study we investigated the expression of TNFalpha of the bone marrow trephine biopsies by immunohistochemical method and the TNFalpha production of peripheral blood mononuclear cells by ELISA method in 15 patients affected by MDS. Five of seven patients without excess of blasts showed high or intermediate TNFalpha expression in the bone marrow biopsies, whereas two patients with excess of blasts were negative and one had low expression. The five CMML patients revealed low or intermediate expression. The production of TNFalpha by the PBMC was analysed in 10 patients, four patients with RA and two with CMML produced higher level of TNFalpha which increased after stimulation with phorbol myristic acetate, but none of the RAEB patients revealed increase in TNFalpha production. In conclusion we suppose that increased TNFalpha expression and production by PBMC may be an indirect evidence of the role of increased apoptosis in low risk MDS patients.  (+info)

Allelic loss in the progression of myelodysplastic syndrome. (8/99)

To elucidate the genetic events that may play an important role in the progression of myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML), we performed allelotype analysis of 24 individuals using matched MDS and AML samples from the same patients. Because the evolution can take years to occur, we used DNAs extracted from archival samples. These samples were analyzed with 79 microsatellite markers, which mapped to each of the autosomal arms except the short arms of the acrocentric chromosomes. Loss of heterozygosity on at least one locus was observed in 18 of the 24 cases (75%) as the disease progressed. Frequent allelic loss in >20% of the informative cases was observed on chromosome arms 6q (31%), 7p (23%), 10p (31%), 11q (27%), 14q (25%), and 20q (23%). Although cytogenetic information was available for many of our cases with allelic loss on 6q, 7p, 10p, 11q, 14q, and 20q, no deletions were observed on these arms. Fractional allelic loss, calculated for each sample as the total number of chromosomal arms lost per total number of arms with information, showed a median value of 0.06 and a mean of 0.15 (range, 0-0.59). No microsatellite instability at more than one marker was found in any of the samples. These results suggest that tumor suppressor genes exist on 6q, 7p, 10p, 11q, 14q, and 20q that have an important role in the evolution of MDS to AML when they are mutated.  (+info)

There are many different types of anemia, each with its own set of causes and symptoms. Some common types of anemia include:

1. Iron-deficiency anemia: This is the most common type of anemia and is caused by a lack of iron in the diet or a problem with the body's ability to absorb iron. Iron is essential for making hemoglobin.
2. Vitamin deficiency anemia: This type of anemia is caused by a lack of vitamins, such as vitamin B12 or folate, that are necessary for red blood cell production.
3. Anemia of chronic disease: This type of anemia is seen in people with chronic diseases, such as kidney disease, rheumatoid arthritis, and cancer.
4. Sickle cell anemia: This is a genetic disorder that affects the structure of hemoglobin and causes red blood cells to be shaped like crescents or sickles.
5. Thalassemia: This is a genetic disorder that affects the production of hemoglobin and can cause anemia, fatigue, and other health problems.

The symptoms of anemia can vary depending on the type and severity of the condition. Common symptoms include fatigue, weakness, pale skin, shortness of breath, and dizziness or lightheadedness. Anemia can be diagnosed with a blood test that measures the number and size of red blood cells, as well as the levels of hemoglobin and other nutrients.

Treatment for anemia depends on the underlying cause of the condition. In some cases, dietary changes or supplements may be sufficient to treat anemia. For example, people with iron-deficiency anemia may need to increase their intake of iron-rich foods or take iron supplements. In other cases, medical treatment may be necessary to address underlying conditions such as kidney disease or cancer.

Preventing anemia is important for maintaining good health and preventing complications. To prevent anemia, it is important to eat a balanced diet that includes plenty of iron-rich foods, vitamin C-rich foods, and other essential nutrients. It is also important to avoid certain substances that can interfere with the absorption of nutrients, such as alcohol and caffeine. Additionally, it is important to manage any underlying medical conditions and seek medical attention if symptoms of anemia persist or worsen over time.

In conclusion, anemia is a common blood disorder that can have significant health implications if left untreated. It is important to be aware of the different types of anemia, their causes, and symptoms in order to seek medical attention if necessary. With proper diagnosis and treatment, many cases of anemia can be successfully managed and prevented.

Symptoms of aplastic anemia may include fatigue, weakness, shortness of breath, pale skin, and increased risk of bleeding or infection. Treatment options for aplastic anemia typically involve blood transfusions and immunosuppressive drugs to stimulate the bone marrow to produce new blood cells. In severe cases, a bone marrow transplant may be necessary.

Overall, aplastic anemia is a rare and serious condition that requires careful management by a healthcare provider to prevent complications and improve quality of life.

Symptoms of hemolytic anemia may include fatigue, weakness, shortness of breath, dizziness, headaches, and pale or yellowish skin. Treatment options depend on the underlying cause but may include blood transfusions, medication to suppress the immune system, antibiotics for infections, and removal of the spleen (splenectomy) in severe cases.

Prevention strategies for hemolytic anemia include avoiding triggers such as certain medications or infections, maintaining good hygiene practices, and seeking early medical attention if symptoms persist or worsen over time.

It is important to note that while hemolytic anemia can be managed with proper treatment, it may not be curable in all cases, and ongoing monitoring and care are necessary to prevent complications and improve quality of life.

There are several subtypes of refractory anemia, including:

1. Refractory anemia with excess blasts (RAEB): This type of anemia is characterized by a high number of immature red blood cells in the bone marrow.
2. Refractory anemia with ringed sideroblasts (RARS): This type of anemia is characterized by the presence of abnormal red blood cells that have a "ring-like" appearance under a microscope.
3. Refractory anemia with multilineage dysplasia (RARMD): This type of anemia is characterized by abnormal cell development in the bone marrow, including immature red blood cells, white blood cells, and platelets.

Refractory anemia can be caused by a variety of factors, including genetic mutations, exposure to certain chemicals or toxins, and certain medical conditions such as chronic kidney disease or rheumatoid arthritis. Treatment for refractory anemia typically involves blood transfusions and supportive care, such as folic acid supplements and antibiotics to prevent infection. In some cases, bone marrow transplantation may be recommended.

There are currently no cures for Fanconi anemia, but bone marrow transplantation and other supportive therapies can help manage some of the symptoms and improve quality of life. Research into the genetics and molecular biology of Fanconi anemia is ongoing to better understand the disorder and develop new treatments.

Some of the common symptoms of Fanconi anemia include short stature, limb deformities, hearing loss, vision problems, and an increased risk of infections and cancer. Children with Fanconi anemia may also experience developmental delays, learning disabilities, and social and emotional challenges.

The diagnosis of Fanconi anemia is typically made based on a combination of clinical findings, laboratory tests, and genetic analysis. Treatment options for Fanconi anemia depend on the severity of the disorder and may include bone marrow transplantation, blood transfusions, antibiotics, and other supportive therapies.

Fanconi anemia is a rare disorder that affects approximately 1 in 160,000 births worldwide. It is more common in certain populations, such as Ashkenazi Jews and individuals of Spanish descent. Fanconi anemia can be inherited in an autosomal recessive pattern, meaning that a child must inherit two copies of the mutated gene (one from each parent) to develop the disorder.

Overall, Fanconi anemia is a complex and rare genetic disorder that requires specialized medical care and ongoing research to better understand its causes and develop effective treatments. With appropriate management and supportive therapies, individuals with Fanconi anemia can lead fulfilling lives despite the challenges associated with the disorder.

Autoimmune hemolytic anemia (AIHA) is a specific type of hemolytic anemia that occurs when the immune system mistakenly attacks and destroys red blood cells. This can happen due to various underlying causes such as infections, certain medications, and some types of cancer.

In autoimmune hemolytic anemia, the immune system produces antibodies that coat the surface of red blood cells and mark them for destruction by other immune cells called complement proteins. This leads to the premature destruction of red blood cells in the spleen, liver, and other organs.

Symptoms of autoimmune hemolytic anemia can include fatigue, weakness, shortness of breath, jaundice (yellowing of the skin and eyes), dark urine, and a pale or yellowish complexion. Treatment options for AIHA depend on the underlying cause of the disorder, but may include medications to suppress the immune system, plasmapheresis to remove antibodies from the blood, and in severe cases, splenectomy (removal of the spleen) or bone marrow transplantation.

In summary, autoimmune hemolytic anemia is a type of hemolytic anemia that occurs when the immune system mistakenly attacks and destroys red blood cells, leading to premature destruction of red blood cells and various symptoms such as fatigue, weakness, and jaundice. Treatment options depend on the underlying cause of the disorder and may include medications, plasmapheresis, and in severe cases, splenectomy or bone marrow transplantation.

In hypochromic anemia, the RBCs are smaller than normal and have a lower concentration of hemoglobin. This can lead to a decrease in the amount of oxygen being carried to the body's tissues, which can cause fatigue, weakness, and shortness of breath.

There are several possible causes of hypochromic anemia, including:

1. Iron deficiency: Iron is essential for the production of hemoglobin, so a lack of iron can lead to a decrease in hemoglobin levels and the development of hypochromic anemia.
2. Vitamin deficiency: Vitamins such as vitamin B12 and folate are important for the production of red blood cells, so a deficiency in these vitamins can lead to hypochromic anemia.
3. Chronic disease: Certain chronic diseases, such as kidney disease, rheumatoid arthritis, and cancer, can lead to hypochromic anemia.
4. Inherited disorders: Certain inherited disorders, such as thalassemia and sickle cell anemia, can cause hypochromic anemia.
5. Autoimmune disorders: Autoimmune disorders, such as autoimmune hemolytic anemia, can cause hypochromic anemia by destroying red blood cells.

Hypochromic anemia is typically diagnosed through a combination of physical examination, medical history, and laboratory tests such as complete blood counts (CBCs) and serum iron studies. Treatment depends on the underlying cause of the anemia and may include dietary changes, supplements, medication, or blood transfusions.

Symptoms of macrocytic anemia may include fatigue, weakness, pale skin, and shortness of breath. Diagnosis is typically made through a complete blood count (CBC) test that shows an elevated mean corpuscular volume (MCV) and reticulocyte count. Treatment depends on the underlying cause, but may include vitamin supplements, changes in medication, or addressing any underlying medical conditions.

In summary, macrocytic anemia is a type of anemia characterized by large red blood cells that are prone to breakdown and can be caused by various factors. It can cause symptoms such as fatigue, weakness, and shortness of breath, and diagnosis is made through a CBC test. Treatment depends on the underlying cause.

Note: The information provided above is a general definition of the medical condition 'Anemia, Pernicious'. It is not meant to be a substitute for professional medical advice or treatment. If you have any concerns about this condition, you should consult a qualified healthcare professional for proper evaluation and care.

The symptoms of sideroblastic anemia can vary depending on the severity of the condition, but may include fatigue, weakness, pale skin, shortness of breath, and a rapid heart rate. Treatment options for sideroblastic anemia typically involve addressing the underlying genetic cause of the condition, such as through gene therapy or enzyme replacement therapy, and managing symptoms with medication and lifestyle modifications.

In summary, sideroblastic anemia is a rare inherited disorder characterized by abnormalities in iron metabolism that can lead to impaired red blood cell production and various other symptoms. It is important for individuals with this condition to receive timely and appropriate medical attention to manage their symptoms and prevent complications.

Sickle cell anemia is caused by mutations in the HBB gene that codes for hemoglobin. The most common mutation is a point mutation at position 6, which replaces the glutamic acid amino acid with a valine (Glu6Val). This substitution causes the hemoglobin molecule to be unstable and prone to forming sickle-shaped cells.

The hallmark symptom of sickle cell anemia is anemia, which is a low number of healthy red blood cells. People with the condition may also experience fatigue, weakness, jaundice (yellowing of the skin and eyes), infections, and episodes of severe pain. Sickle cell anemia can also increase the risk of stroke, heart disease, and other complications.

Sickle cell anemia is diagnosed through blood tests that measure hemoglobin levels and the presence of sickle cells. Treatment typically involves managing symptoms and preventing complications with medications, blood transfusions, and antibiotics. In some cases, bone marrow transplantation may be recommended.

Prevention of sickle cell anemia primarily involves avoiding the genetic mutations that cause the condition. This can be done through genetic counseling and testing for individuals who have a family history of the condition or are at risk of inheriting it. Prenatal testing is also available for pregnant women who may be carriers of the condition.

Overall, sickle cell anemia is a serious genetic disorder that can significantly impact quality of life and life expectancy if left untreated. However, with proper management and care, individuals with the condition can lead fulfilling lives and manage their symptoms effectively.

The term "refractory" refers to the fact that this type of anemia does not respond well to standard treatments, such as blood transfusions or medications. The term "excess blasts" refers to the presence of a large number of immature cells in the bone marrow.

RAEB is a serious and potentially life-threatening condition that can develop into acute myeloid leukemia (AML), a type of cancer that affects the blood and bone marrow. AML is characterized by the rapid growth of abnormal white blood cells, which can crowd out normal cells in the bone marrow and lead to a variety of symptoms, including fatigue, fever, night sweats, and weight loss.

RAEB is usually diagnosed in adults over the age of 60, although it can occur at any age. The condition is often associated with other health problems, such as myelodysplastic syndrome (MDS), a group of disorders that affect the bone marrow and blood cells.

Treatment for RAEB typically involves chemotherapy and/or bone marrow transplantation. The goal of treatment is to slow the progression of the disease, reduce symptoms, and improve quality of life. In some cases, RAEB may be managed with supportive care, such as blood transfusions and antibiotics, to help manage symptoms and prevent complications.

Overall, refractory anemia with excess blasts is a serious and complex condition that requires careful management by a healthcare team of hematologists, oncologists, and other specialists. With appropriate treatment, many people with RAEB are able to achieve long-term remission and improve their quality of life.

Symptoms of megaloblastic anemia may include fatigue, weakness, shortness of breath, pale skin, and weight loss. The condition is typically diagnosed through a physical examination, blood tests (including a complete blood count and blood chemistry tests), and possibly a bone marrow biopsy.

Treatment for megaloblastic anemia usually involves addressing the underlying cause of the condition, such as vitamin B12 or folate supplements. In some cases, medications to stimulate the production of red blood cells may be prescribed. If left untreated, megaloblastic anemia can lead to complications such as heart problems and increased risk of infections.

Prevalence: Anemia, hemolytic, congenital is a rare disorder, affecting approximately 1 in 100,000 to 1 in 200,000 births.

Causes: The condition is caused by mutations in genes that code for proteins involved in hemoglobin synthesis or red blood cell membrane structure. These mutations can lead to abnormal hemoglobin formation, red blood cell membrane instability, and increased susceptibility to oxidative stress, which can result in hemolytic anemia.

Symptoms: Symptoms of anemia, hemolytic, congenital may include jaundice (yellowing of the skin and eyes), fatigue, weakness, pale skin, and shortness of breath. In severe cases, the condition can lead to life-threatening complications such as anemia, infections, and kidney failure.

Diagnosis: Anemia, hemolytic, congenital is typically diagnosed through a combination of physical examination, medical history, and laboratory tests, including blood smear examination, hemoglobin electrophoresis, and mutation analysis.

Treatment: Treatment for anemia, hemolytic, congenital depends on the specific underlying genetic cause and may include blood transfusions, folic acid supplements, antibiotics, and/or surgery to remove the spleen. In some cases, bone marrow transplantation may be necessary.

Prognosis: The prognosis for anemia, hemolytic, congenital varies depending on the specific underlying genetic cause and the severity of the condition. With appropriate treatment, many individuals with this condition can lead relatively normal lives, but in severe cases, the condition can be life-threatening.

The symptoms of EIA can vary in severity and may include fever, loss of appetite, weight loss, depression, and anemia. In severe cases, the disease can lead to death. There is no cure for EIA, but it can be managed with antiretroviral medications and supportive care.

EIA is a significant concern in the equine industry, as infected animals can transmit the disease to other horses and can be a risk to human health. Testing for EIA is done through a blood test, and infected animals are typically euthanized to prevent the spread of the disease.

Previous article Definition of 'Anemia, Sideroblastic, Congenital' Next article Definition of 'Anemia, Diamond-Blackfan'

Source: Genetic Home Reference: NIH

Recurrence can also refer to the re-emergence of symptoms in a previously treated condition, such as a chronic pain condition that returns after a period of remission.

In medical research, recurrence is often studied to understand the underlying causes of disease progression and to develop new treatments and interventions to prevent or delay its return.

1. Iron deficiency anemia: This is the most common hematologic complication of pregnancy, caused by the increased demand for iron and the potential for poor dietary intake or gastrointestinal blood loss.
2. Thrombocytopenia: A decrease in platelet count, which can be mild and resolve spontaneously or severe and require treatment.
3. Leukemia: Rare but potentially serious, leukemia can occur during pregnancy and may require prompt intervention to ensure the health of both the mother and the fetus.
4. Thrombosis: The formation of a blood clot in a blood vessel, which can be life-threatening for both the mother and the baby if left untreated.
5. Hemorrhage: Excessive bleeding during pregnancy, which can be caused by various factors such as placenta previa or abruption.
6. Preeclampsia: A condition characterized by high blood pressure and damage to organs such as the kidneys and liver, which can increase the risk of hemorrhage and other complications.
7. Ectopic pregnancy: A pregnancy that develops outside of the uterus, often in the fallopian tube, which can cause severe bleeding and be life-threatening if left untreated.

A condition where newborn babies have a lower than normal number of red blood cells or low levels of hemoglobin in their blood. The condition can be caused by various factors such as premature birth, low birth weight, infections, and genetic disorders. Symptoms may include jaundice, fatigue, and difficulty breathing. Treatment options may vary depending on the underlying cause but may include blood transfusions and iron supplements.

Example usage: "Neonatal anemia is a common condition in newborn babies that can be caused by various factors such as premature birth or low birth weight."

Pallor is often used as an indicator of underlying disease, particularly in conditions where there is a decrease in the amount of hemoglobin in the blood, such as anemia or blood loss. It can also be a sign of other diseases such as liver cirrhosis, kidney failure, and some types of cancer.

There are different types of pallor, including:

1. Anemic pallor: This is the most common type of pallor and is caused by a decrease in the number of red blood cells or hemoglobin in the blood. It can be seen in conditions such as iron deficiency anemia, vitamin deficiency anemia, and sickle cell anemia.
2. Post-inflammatory pallor: This type of pallor is caused by inflammation that leads to a decrease in blood flow to the skin. It can be seen in conditions such as erythema migrans (Lyme disease), and other inflammatory conditions.
3. Cirrhotic pallor: This type of pallor is caused by liver cirrhosis and is characterized by a pale, washed-out appearance of the skin.
4. Renal pallor: This type of pallor is caused by kidney failure and is characterized by a pale, washed-out appearance of the skin.
5. Cancer pallor: This type of pallor is caused by certain types of cancer, such as carcinomas and lymphomas, and is characterized by a pale, washed-out appearance of the skin.

In summary, pallor is a term used to describe an abnormal paleness or whiteness of the skin that can be caused by a variety of underlying medical conditions. It is often used as an indicator of illness and can be seen in a wide range of conditions, including anemia, inflammation, liver cirrhosis, kidney failure, and certain types of cancer.

There are several possible causes of thrombocytopenia, including:

1. Immune-mediated disorders such as idiopathic thrombocytopenic purpura (ITP) or systemic lupus erythematosus (SLE).
2. Bone marrow disorders such as aplastic anemia or leukemia.
3. Viral infections such as HIV or hepatitis C.
4. Medications such as chemotherapy or non-steroidal anti-inflammatory drugs (NSAIDs).
5. Vitamin deficiencies, especially vitamin B12 and folate.
6. Genetic disorders such as Bernard-Soulier syndrome.
7. Sepsis or other severe infections.
8. Disseminated intravascular coagulation (DIC), a condition where blood clots form throughout the body.
9. Postpartum thrombocytopenia, which can occur in some women after childbirth.

Symptoms of thrombocytopenia may include easy bruising, petechiae (small red or purple spots on the skin), and prolonged bleeding from injuries or surgical sites. Treatment options depend on the underlying cause but may include platelet transfusions, steroids, immunosuppressive drugs, and in severe cases, surgery.

In summary, thrombocytopenia is a condition characterized by low platelet counts that can increase the risk of bleeding and bruising. It can be caused by various factors, and treatment options vary depending on the underlying cause.

The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the World Health Organization (WHO). In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.

In this article, we will explore the definition and impact of chronic diseases, as well as strategies for managing and living with them. We will also discuss the importance of early detection and prevention, as well as the role of healthcare providers in addressing the needs of individuals with chronic diseases.

What is a Chronic Disease?

A chronic disease is a condition that lasts for an extended period of time, often affecting daily life and activities. Unlike acute diseases, which have a specific beginning and end, chronic diseases are long-term and persistent. Examples of chronic diseases include:

1. Diabetes
2. Heart disease
3. Arthritis
4. Asthma
5. Cancer
6. Chronic obstructive pulmonary disease (COPD)
7. Chronic kidney disease (CKD)
8. Hypertension
9. Osteoporosis
10. Stroke

Impact of Chronic Diseases

The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the WHO. In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.

Chronic diseases can also have a significant impact on an individual's quality of life, limiting their ability to participate in activities they enjoy and affecting their relationships with family and friends. Moreover, the financial burden of chronic diseases can lead to poverty and reduce economic productivity, thus having a broader societal impact.

Addressing Chronic Diseases

Given the significant burden of chronic diseases, it is essential that we address them effectively. This requires a multi-faceted approach that includes:

1. Lifestyle modifications: Encouraging healthy behaviors such as regular physical activity, a balanced diet, and smoking cessation can help prevent and manage chronic diseases.
2. Early detection and diagnosis: Identifying risk factors and detecting diseases early can help prevent or delay their progression.
3. Medication management: Effective medication management is crucial for controlling symptoms and slowing disease progression.
4. Multi-disciplinary care: Collaboration between healthcare providers, patients, and families is essential for managing chronic diseases.
5. Health promotion and disease prevention: Educating individuals about the risks of chronic diseases and promoting healthy behaviors can help prevent their onset.
6. Addressing social determinants of health: Social determinants such as poverty, education, and employment can have a significant impact on health outcomes. Addressing these factors is essential for reducing health disparities and improving overall health.
7. Investing in healthcare infrastructure: Investing in healthcare infrastructure, technology, and research is necessary to improve disease detection, diagnosis, and treatment.
8. Encouraging policy change: Policy changes can help create supportive environments for healthy behaviors and reduce the burden of chronic diseases.
9. Increasing public awareness: Raising public awareness about the risks and consequences of chronic diseases can help individuals make informed decisions about their health.
10. Providing support for caregivers: Chronic diseases can have a significant impact on family members and caregivers, so providing them with support is essential for improving overall health outcomes.

Conclusion

Chronic diseases are a major public health burden that affect millions of people worldwide. Addressing these diseases requires a multi-faceted approach that includes lifestyle changes, addressing social determinants of health, investing in healthcare infrastructure, encouraging policy change, increasing public awareness, and providing support for caregivers. By taking a comprehensive approach to chronic disease prevention and management, we can improve the health and well-being of individuals and communities worldwide.

Neoplasm refers to an abnormal growth of cells that can be benign (non-cancerous) or malignant (cancerous). Neoplasms can occur in any part of the body and can affect various organs and tissues. The term "neoplasm" is often used interchangeably with "tumor," but while all tumors are neoplasms, not all neoplasms are tumors.

Types of Neoplasms

There are many different types of neoplasms, including:

1. Carcinomas: These are malignant tumors that arise in the epithelial cells lining organs and glands. Examples include breast cancer, lung cancer, and colon cancer.
2. Sarcomas: These are malignant tumors that arise in connective tissue, such as bone, cartilage, and fat. Examples include osteosarcoma (bone cancer) and soft tissue sarcoma.
3. Lymphomas: These are cancers of the immune system, specifically affecting the lymph nodes and other lymphoid tissues. Examples include Hodgkin lymphoma and non-Hodgkin lymphoma.
4. Leukemias: These are cancers of the blood and bone marrow that affect the white blood cells. Examples include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
5. Melanomas: These are malignant tumors that arise in the pigment-producing cells called melanocytes. Examples include skin melanoma and eye melanoma.

Causes and Risk Factors of Neoplasms

The exact causes of neoplasms are not fully understood, but there are several known risk factors that can increase the likelihood of developing a neoplasm. These include:

1. Genetic predisposition: Some people may be born with genetic mutations that increase their risk of developing certain types of neoplasms.
2. Environmental factors: Exposure to certain environmental toxins, such as radiation and certain chemicals, can increase the risk of developing a neoplasm.
3. Infection: Some neoplasms are caused by viruses or bacteria. For example, human papillomavirus (HPV) is a common cause of cervical cancer.
4. Lifestyle factors: Factors such as smoking, excessive alcohol consumption, and a poor diet can increase the risk of developing certain types of neoplasms.
5. Family history: A person's risk of developing a neoplasm may be higher if they have a family history of the condition.

Signs and Symptoms of Neoplasms

The signs and symptoms of neoplasms can vary depending on the type of cancer and where it is located in the body. Some common signs and symptoms include:

1. Unusual lumps or swelling
2. Pain
3. Fatigue
4. Weight loss
5. Change in bowel or bladder habits
6. Unexplained bleeding
7. Coughing up blood
8. Hoarseness or a persistent cough
9. Changes in appetite or digestion
10. Skin changes, such as a new mole or a change in the size or color of an existing mole.

Diagnosis and Treatment of Neoplasms

The diagnosis of a neoplasm usually involves a combination of physical examination, imaging tests (such as X-rays, CT scans, or MRI scans), and biopsy. A biopsy involves removing a small sample of tissue from the suspected tumor and examining it under a microscope for cancer cells.

The treatment of neoplasms depends on the type, size, location, and stage of the cancer, as well as the patient's overall health. Some common treatments include:

1. Surgery: Removing the tumor and surrounding tissue can be an effective way to treat many types of cancer.
2. Chemotherapy: Using drugs to kill cancer cells can be effective for some types of cancer, especially if the cancer has spread to other parts of the body.
3. Radiation therapy: Using high-energy radiation to kill cancer cells can be effective for some types of cancer, especially if the cancer is located in a specific area of the body.
4. Immunotherapy: Boosting the body's immune system to fight cancer can be an effective treatment for some types of cancer.
5. Targeted therapy: Using drugs or other substances to target specific molecules on cancer cells can be an effective treatment for some types of cancer.

Prevention of Neoplasms

While it is not always possible to prevent neoplasms, there are several steps that can reduce the risk of developing cancer. These include:

1. Avoiding exposure to known carcinogens (such as tobacco smoke and radiation)
2. Maintaining a healthy diet and lifestyle
3. Getting regular exercise
4. Not smoking or using tobacco products
5. Limiting alcohol consumption
6. Getting vaccinated against certain viruses that are associated with cancer (such as human papillomavirus, or HPV)
7. Participating in screening programs for early detection of cancer (such as mammograms for breast cancer and colonoscopies for colon cancer)
8. Avoiding excessive exposure to sunlight and using protective measures such as sunscreen and hats to prevent skin cancer.

It's important to note that not all cancers can be prevented, and some may be caused by factors that are not yet understood or cannot be controlled. However, by taking these steps, individuals can reduce their risk of developing cancer and improve their overall health and well-being.

Multiple myeloma is the second most common type of hematologic cancer after non-Hodgkin's lymphoma, accounting for approximately 1% of all cancer deaths worldwide. It is more common in older adults, with most patients being diagnosed over the age of 65.

The exact cause of multiple myeloma is not known, but it is believed to be linked to genetic mutations that occur in the plasma cells. There are several risk factors that have been associated with an increased risk of developing multiple myeloma, including:

1. Family history: Having a family history of multiple myeloma or other plasma cell disorders increases the risk of developing the disease.
2. Age: The risk of developing multiple myeloma increases with age, with most patients being diagnosed over the age of 65.
3. Race: African Americans are at higher risk of developing multiple myeloma than other races.
4. Obesity: Being overweight or obese may increase the risk of developing multiple myeloma.
5. Exposure to certain chemicals: Exposure to certain chemicals such as pesticides, solvents, and heavy metals has been linked to an increased risk of developing multiple myeloma.

The symptoms of multiple myeloma can vary depending on the severity of the disease and the organs affected. Common symptoms include:

1. Bone pain: Pain in the bones, particularly in the spine, ribs, or long bones, is a common symptom of multiple myeloma.
2. Fatigue: Feeling tired or weak is another common symptom of the disease.
3. Infections: Patients with multiple myeloma may be more susceptible to infections due to the impaired functioning of their immune system.
4. Bone fractures: Weakened bones can lead to an increased risk of fractures, particularly in the spine, hips, or ribs.
5. Kidney problems: Multiple myeloma can cause damage to the kidneys, leading to problems such as kidney failure or proteinuria (excess protein in the urine).
6. Anemia: A low red blood cell count can cause anemia, which can lead to fatigue, weakness, and shortness of breath.
7. Increased calcium levels: High levels of calcium in the blood can cause symptoms such as nausea, vomiting, constipation, and confusion.
8. Neurological problems: Multiple myeloma can cause neurological problems such as headaches, numbness or tingling in the arms and legs, and difficulty with coordination and balance.

The diagnosis of multiple myeloma typically involves a combination of physical examination, medical history, and laboratory tests. These may include:

1. Complete blood count (CBC): A CBC can help identify abnormalities in the numbers and characteristics of different types of blood cells, including red blood cells, white blood cells, and platelets.
2. Serum protein electrophoresis (SPEP): This test measures the levels of different proteins in the blood, including immunoglobulins (antibodies) and abnormal proteins produced by myeloma cells.
3. Urine protein electrophoresis (UPEP): This test measures the levels of different proteins in the urine.
4. Immunofixation: This test is used to identify the type of antibody produced by myeloma cells and to rule out other conditions that may cause similar symptoms.
5. Bone marrow biopsy: A bone marrow biopsy involves removing a sample of tissue from the bone marrow for examination under a microscope. This can help confirm the diagnosis of multiple myeloma and determine the extent of the disease.
6. Imaging tests: Imaging tests such as X-rays, CT scans, or MRI scans may be used to assess the extent of bone damage or other complications of multiple myeloma.
7. Genetic testing: Genetic testing may be used to identify specific genetic abnormalities that are associated with multiple myeloma and to monitor the response of the disease to treatment.

It's important to note that not all patients with MGUS or smoldering myeloma will develop multiple myeloma, and some patients with multiple myeloma may not have any symptoms at all. However, if you are experiencing any of the symptoms listed above or have a family history of multiple myeloma, it's important to talk to your doctor about your risk and any tests that may be appropriate for you.

There are many different types of epilepsy, each with its own unique set of symptoms and characteristics. Some common forms of epilepsy include:

1. Generalized Epilepsy: This type of epilepsy affects both sides of the brain and can cause a range of seizure types, including absence seizures, tonic-clonic seizures, and atypical absence seizures.
2. Focal Epilepsy: This type of epilepsy affects only one part of the brain and can cause seizures that are localized to that area. There are several subtypes of focal epilepsy, including partial seizures with complex symptoms and simple partial seizures.
3. Tonic-Clonic Epilepsy: This type of epilepsy is also known as grand mal seizures and can cause a loss of consciousness, convulsions, and muscle stiffness.
4. Lennox-Gastaut Syndrome: This is a rare and severe form of epilepsy that typically develops in early childhood and can cause multiple types of seizures, including tonic, atonic, and myoclonic seizures.
5. Dravet Syndrome: This is a rare genetic form of epilepsy that typically develops in infancy and can cause severe, frequent seizures.
6. Rubinstein-Taybi Syndrome: This is a rare genetic disorder that can cause intellectual disability, developmental delays, and various types of seizures.
7. Other forms of epilepsy include Absence Epilepsy, Myoclonic Epilepsy, and Atonic Epilepsy.

The symptoms of epilepsy can vary widely depending on the type of seizure disorder and the individual affected. Some common symptoms of epilepsy include:

1. Seizures: This is the most obvious symptom of epilepsy and can range from mild to severe.
2. Loss of consciousness: Some people with epilepsy may experience a loss of consciousness during a seizure, while others may remain aware of their surroundings.
3. Confusion and disorientation: After a seizure, some people with epilepsy may feel confused and disoriented.
4. Memory loss: Seizures can cause short-term or long-term memory loss.
5. Fatigue: Epilepsy can cause extreme fatigue, both during and after a seizure.
6. Emotional changes: Some people with epilepsy may experience emotional changes, such as anxiety, depression, or mood swings.
7. Cognitive changes: Epilepsy can affect cognitive function, including attention, memory, and learning.
8. Sleep disturbances: Some people with epilepsy may experience sleep disturbances, such as insomnia or sleepiness.
9. Physical symptoms: Depending on the type of seizure, people with epilepsy may experience physical symptoms such as muscle weakness, numbness or tingling, and sensory changes.
10. Social isolation: Epilepsy can cause social isolation due to fear of having a seizure in public or stigma associated with the condition.

It's important to note that not everyone with epilepsy will experience all of these symptoms, and some people may have different symptoms depending on the type of seizure they experience. Additionally, some people with epilepsy may experience additional symptoms not listed here.

Symptoms of pancytopenia may include fatigue, weakness, shortness of breath, and increased risk of bleeding or infection. Treatment depends on the underlying cause, but may include blood transfusions, antibiotics, or immunosuppressive medications. In severe cases, pancytopenia can lead to anemia, infections, or bleeding complications that can be life-threatening.

Previous Entry ‘Pancytopenia’ in the medical field.
Next Entry What are the symptoms of pancytopenia?

There are several subtypes of NHL, including:

1. B-cell lymphomas (such as diffuse large B-cell lymphoma and follicular lymphoma)
2. T-cell lymphomas (such as peripheral T-cell lymphoma and mycosis fungoides)
3. Natural killer cell lymphomas (such as nasal NK/T-cell lymphoma)
4. Histiocyte-rich B-cell lymphoma
5. Primary mediastinal B-cell lymphoma
6. Mantle cell lymphoma
7. Waldenström macroglobulinemia
8. Lymphoplasmacytoid lymphoma
9. Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) related lymphoma

These subtypes can be further divided into other categories based on the specific characteristics of the cancer cells.

Symptoms of NHL can vary depending on the location and size of the tumor, but may include:

* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching
* Abdominal pain
* Swollen spleen

Treatment for NHL typically involves a combination of chemotherapy, radiation therapy, and in some cases, targeted therapy or immunotherapy. The specific treatment plan will depend on the subtype of NHL, the stage of the cancer, and other individual factors.

Overall, NHL is a complex and diverse group of cancers that require specialized care from a team of medical professionals, including hematologists, oncologists, radiation therapists, and other support staff. With advances in technology and treatment options, many people with NHL can achieve long-term remission or a cure.

Causes:

* Dietary deficiency due to a lack of animal products in the diet
* Malabsorption due to gastrointestinal disorders such as Crohn's disease or celiac disease
* Pernicious anemia, an autoimmune condition that affects the absorption of vitamin B12 in the gut.
* Surgical removal of part of the small intestine
* Certain medications such as metformin and proton pump inhibitors

Symptoms:

* Fatigue, weakness, and shortness of breath
* Pale skin and mouth sores
* Difficulty walking or balance problems
* Numbness or tingling sensations in the hands and feet
* Memory loss and depression
* Poor appetite and weight loss

Diagnosis:

* Blood tests to measure vitamin B12 levels and other related markers such as homocysteine
* Physical examination and medical history to identify risk factors or signs of deficiency

Treatment:

* Dietary changes to include more animal products such as meat, fish, eggs, and dairy products.
* Vitamin B12 supplements in the form of tablets, lozenges, or injections.
* Addressing underlying conditions that may be contributing to the deficiency such as gastrointestinal disorders.

Prevention:

* Consuming animal products as part of a balanced diet
* Avoiding medications that can interfere with vitamin B12 absorption.

Hodgkin Disease can spread to other parts of the body through the lymphatic system, and it can affect people of all ages, although it is most common in young adults and teenagers. The symptoms of Hodgkin Disease can vary depending on the stage of the disease, but they may include swollen lymph nodes, fever, night sweats, fatigue, weight loss, and itching.

There are several types of Hodgkin Disease, including:

* Classical Hodgkin Disease: This is the most common type of Hodgkin Disease and is characterized by the presence of Reed-Sternberg cells.
* Nodular Lymphocytic predominant Hodgkin Disease: This type of Hodgkin Disease is characterized by the presence of nodules in the lymph nodes.
* Mixed Cellularity Hodgkin Disease: This type of Hodgkin Disease is characterized by a mixture of Reed-Sternberg cells and other immune cells.

Hodgkin Disease is usually diagnosed with a biopsy, which involves removing a sample of tissue from the affected lymph node or other area and examining it under a microscope for cancer cells. Treatment for Hodgkin Disease typically involves chemotherapy, radiation therapy, or a combination of both. In some cases, bone marrow or stem cell transplantation may be necessary.

The prognosis for Hodgkin Disease is generally good, especially if the disease is detected and treated early. According to the American Cancer Society, the 5-year survival rate for people with Hodgkin Disease is about 85%. However, the disease can sometimes recur after treatment, and the long-term effects of radiation therapy and chemotherapy can include infertility, heart problems, and an increased risk of secondary cancers.

Hodgkin Disease is a rare form of cancer that affects the immune system. It is most commonly diagnosed in young adults and is usually treatable with chemotherapy or radiation therapy. However, the disease can sometimes recur after treatment, and the long-term effects of treatment can include infertility, heart problems, and an increased risk of secondary cancers.

Examples of hematologic diseases include:

1. Anemia - a condition where there are not enough red blood cells or hemoglobin in the body.
2. Leukemia - a type of cancer that affects the bone marrow and blood, causing an overproduction of immature white blood cells.
3. Lymphoma - a type of cancer that affects the lymphatic system, including the bone marrow, spleen, and lymph nodes.
4. Thalassemia - a genetic disorder that affects the production of hemoglobin, leading to anemia and other complications.
5. Sickle cell disease - a genetic disorder that affects the production of hemoglobin, causing red blood cells to become sickle-shaped and prone to breaking down.
6. Polycythemia vera - a rare disorder where there is an overproduction of red blood cells.
7. Myelodysplastic syndrome - a condition where the bone marrow produces abnormal blood cells that do not mature properly.
8. Myeloproliferative neoplasms - a group of conditions where the bone marrow produces excessive amounts of blood cells, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
9. Deep vein thrombosis - a condition where a blood clot forms in a deep vein, often in the leg or arm.
10. Pulmonary embolism - a condition where a blood clot travels to the lungs and blocks a blood vessel, causing shortness of breath, chest pain, and other symptoms.

These are just a few examples of hematologic diseases, but there are many others that can affect the blood and bone marrow. Treatment options for these diseases can range from watchful waiting and medication to surgery, chemotherapy, and stem cell transplantation. It is important to seek medical attention if you experience any symptoms of hematologic disease, as early diagnosis and treatment can improve outcomes.

There are two main types of beta-thalassemia:

1. Beta-thalassemia major (also known as Cooley's anemia): This is the most severe form of the condition, and it can cause serious health problems and a shortened lifespan if left untreated. Children with this condition are typically diagnosed at birth or in early childhood, and they may require regular blood transfusions and other medical interventions to manage their symptoms and prevent complications.
2. Beta-thalassemia minor (also known as thalassemia trait): This is a milder form of the condition, and it may not cause any noticeable symptoms. People with beta-thalassemia minor have one mutated copy of the HBB gene and one healthy copy, which allows them to produce some normal hemoglobin. However, they may still be at risk for complications such as anemia, fatigue, and a higher risk of infections.

The symptoms of beta-thalassemia can vary depending on the severity of the condition and the age of onset. Common symptoms include:

* Fatigue
* Weakness
* Pale skin
* Shortness of breath
* Frequent infections
* Yellowing of the skin and eyes (jaundice)
* Enlarged spleen

Beta-thalassemia is most commonly found in people of Mediterranean, African, and Southeast Asian ancestry. It is caused by mutations in the HBB gene, which is inherited from one's parents. There is no cure for beta-thalassemia, but it can be managed with blood transfusions, chelation therapy, and other medical interventions. Bone marrow transplantation may also be a viable option for some patients.

In conclusion, beta-thalassemia is a genetic disorder that affects the production of hemoglobin, leading to anemia, fatigue, and other complications. While there is no cure for the condition, it can be managed with medical interventions and bone marrow transplantation may be a viable option for some patients. Early diagnosis and management are crucial in preventing or minimizing the complications of beta-thalassemia.

This definition of 'Neoplasm Recurrence, Local' is from the Healthcare Professionals edition of the Merriam-Webster Medical Dictionary, copyright © 2007 by Merriam-Webster, Inc.

There are several different types of malaria, including:

1. Plasmodium falciparum: This is the most severe form of malaria, and it can be fatal if left untreated. It is found in many parts of the world, including Africa, Asia, and Latin America.
2. Plasmodium vivax: This type of malaria is less severe than P. falciparum, but it can still cause serious complications if left untreated. It is found in many parts of the world, including Africa, Asia, and Latin America.
3. Plasmodium ovale: This type of malaria is similar to P. vivax, but it can cause more severe symptoms in some people. It is found primarily in West Africa.
4. Plasmodium malariae: This type of malaria is less common than the other three types, and it tends to cause milder symptoms. It is found primarily in parts of Africa and Asia.

The symptoms of malaria can vary depending on the type of parasite that is causing the infection, but they typically include:

1. Fever
2. Chills
3. Headache
4. Muscle and joint pain
5. Fatigue
6. Nausea and vomiting
7. Diarrhea
8. Anemia (low red blood cell count)

If malaria is not treated promptly, it can lead to more severe complications, such as:

1. Seizures
2. Coma
3. Respiratory failure
4. Kidney failure
5. Liver failure
6. Anemia (low red blood cell count)

Malaria is typically diagnosed through a combination of physical examination, medical history, and laboratory tests, such as blood smears or polymerase chain reaction (PCR) tests. Treatment for malaria typically involves the use of antimalarial drugs, such as chloroquine or artemisinin-based combination therapies. In severe cases, hospitalization may be necessary to manage complications and provide supportive care.

Prevention is an important aspect of managing malaria, and this can include:

1. Using insecticide-treated bed nets
2. Wearing protective clothing and applying insect repellent when outdoors
3. Eliminating standing water around homes and communities to reduce the number of mosquito breeding sites
4. Using indoor residual spraying (IRS) or insecticide-treated wall lining to kill mosquitoes
5. Implementing malaria control measures in areas where malaria is common, such as distribution of long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS)
6. Improving access to healthcare services, particularly in rural and remote areas
7. Providing education and awareness about malaria prevention and control
8. Encouraging the use of preventive medications, such as intermittent preventive treatment (IPT) for pregnant women and children under the age of five.

Early diagnosis and prompt treatment are critical in preventing the progression of malaria and reducing the risk of complications and death. In areas where malaria is common, it is essential to have access to reliable diagnostic tools and effective antimalarial drugs.

Intractable pain can have a significant impact on an individual's quality of life, affecting their ability to perform daily activities, sleep, and overall well-being. Treatment for intractable pain often involves a combination of medications and alternative therapies such as physical therapy, acupuncture, or cognitive behavioral therapy.

Some common symptoms of intractable pain include:

* Chronic and persistent pain that does not respond to treatment
* Pain that is severe and debilitating
* Pain that affects daily activities and quality of life
* Pain that is burning, shooting, stabbing, or cramping in nature
* Pain that is localized to a specific area of the body or widespread
* Pain that is accompanied by other symptoms such as fatigue, anxiety, or depression.

Intractable pain can be caused by a variety of factors, including:

* Nerve damage or nerve damage from injury or disease
* Inflammation or swelling in the body
* Chronic conditions like arthritis, fibromyalgia, or migraines
* Infections such as shingles or Lyme disease
* Cancer or its treatment
* Neurological disorders such as multiple sclerosis or Parkinson's disease.

Managing intractable pain can be challenging and may involve a multidisciplinary approach, including:

* Medications such as pain relievers, anti-inflammatory drugs, or muscle relaxants
* Alternative therapies such as physical therapy, acupuncture, or cognitive behavioral therapy
* Lifestyle changes such as regular exercise, stress management techniques, and a healthy diet
* Interventional procedures such as nerve blocks or spinal cord stimulation.

It is important to work closely with a healthcare provider to find the most effective treatment plan for managing intractable pain. With the right combination of medications and alternative therapies, many people are able to manage their pain and improve their quality of life.

Symptoms of neutropenia may include recurring infections, fever, fatigue, weight loss, and swollen lymph nodes. The diagnosis is typically made through a blood test that measures the number of neutrophils in the blood.

Treatment options for neutropenia depend on the underlying cause but may include antibiotics, supportive care to manage symptoms, and in severe cases, bone marrow transplantation or granulocyte-colony stimulating factor (G-CSF) therapy to increase neutrophil production.

There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia. Alpha-thalassemia is caused by abnormalities in the production of the alpha-globin chain, which is one of the two chains that make up hemoglobin. Beta-thalassemia is caused by abnormalities in the production of the beta-globin chain.

Thalassemia can cause a range of symptoms, including anemia, fatigue, pale skin, and shortness of breath. In severe cases, it can lead to life-threatening complications such as heart failure, liver failure, and bone deformities. Thalassemia is usually diagnosed through blood tests that measure the levels of hemoglobin and other proteins in the blood.

There is no cure for thalassemia, but treatment can help manage the symptoms and prevent complications. Treatment may include blood transfusions, folic acid supplements, and medications to reduce the severity of anemia. In some cases, bone marrow transplantation may be recommended.

Preventive measures for thalassemia include genetic counseling and testing for individuals who are at risk of inheriting the disorder. Prenatal testing is also available for pregnant women who are carriers of the disorder. In addition, individuals with thalassemia should avoid marriage within their own family or community to reduce the risk of passing on the disorder to their children.

Overall, thalassemia is a serious and inherited blood disorder that can have significant health implications if left untreated. However, with proper treatment and management, individuals with thalassemia can lead fulfilling lives and minimize the risk of complications.

The term splenomegaly is used to describe any condition that results in an increase in the size of the spleen, regardless of the underlying cause. This can be caused by a variety of factors, such as infection, inflammation, cancer, or genetic disorders.

Splenomegaly can be diagnosed through a physical examination, where the doctor may feel the enlarged spleen during an abdominal palpation. Imaging tests, such as ultrasound, computed tomography (CT) scans, or magnetic resonance imaging (MRI), may also be used to confirm the diagnosis and evaluate the extent of the splenomegaly.

Treatment for splenomegaly depends on the underlying cause. For example, infections such as malaria or mononucleosis are treated with antibiotics, while cancerous conditions may require surgical intervention or chemotherapy. In some cases, the spleen may need to be removed, a procedure known as splenectomy.

In conclusion, splenomegaly is an abnormal enlargement of the spleen that can be caused by various factors and requires prompt medical attention for proper diagnosis and treatment.

Partial epilepsy can be further divided into several subtypes based on the location of the affected brain area, including:

1. Temporal lobe partial epilepsy: This type of partial epilepsy affects the temporal lobe of the brain and can cause seizures that are accompanied by changes in mood, behavior, or cognitive function.
2. Frontal lobe partial epilepsy: This type of partial epilepsy affects the frontal lobe of the brain and can cause seizures that are accompanied by changes in personality, behavior, or movement.
3. Parietal lobe partial epilepsy: This type of partial epilepsy affects the parietal lobe of the brain and can cause seizures that are accompanied by sensory symptoms, such as numbness or tingling in the affected limbs.
4. Occipital lobe partial epilepsy: This type of partial epilepsy affects the occipital lobe of the brain and can cause seizures that are accompanied by visual disturbances, such as flashing lights or blind spots.
5. Temporomesial partial epilepsy: This type of partial epilepsy affects both the temporal and mesial (frontal) lobes of the brain and can cause seizures that are accompanied by changes in mood, behavior, or cognitive function.

Partial epilepsy is typically diagnosed through a combination of medical history, physical examination, and diagnostic tests such as electroencephalography (EEG) or magnetic resonance imaging (MRI). Treatment for partial epilepsy may involve medications, surgery, or other interventions, depending on the specific type and severity of the condition.

A condition in which the kidneys gradually lose their function over time, leading to the accumulation of waste products in the body. Also known as chronic kidney disease (CKD).

Prevalence:

Chronic kidney failure affects approximately 20 million people worldwide and is a major public health concern. In the United States, it is estimated that 1 in 5 adults has CKD, with African Americans being disproportionately affected.

Causes:

The causes of chronic kidney failure are numerous and include:

1. Diabetes: High blood sugar levels can damage the kidneys over time.
2. Hypertension: Uncontrolled high blood pressure can cause damage to the blood vessels in the kidneys.
3. Glomerulonephritis: An inflammation of the glomeruli, the tiny blood vessels in the kidneys that filter waste and excess fluids from the blood.
4. Interstitial nephritis: Inflammation of the tissue between the kidney tubules.
5. Pyelonephritis: Infection of the kidneys, usually caused by bacteria or viruses.
6. Polycystic kidney disease: A genetic disorder that causes cysts to grow on the kidneys.
7. Obesity: Excess weight can increase blood pressure and strain on the kidneys.
8. Family history: A family history of kidney disease increases the risk of developing chronic kidney failure.

Symptoms:

Early stages of chronic kidney failure may not cause any symptoms, but as the disease progresses, symptoms can include:

1. Fatigue: Feeling tired or weak.
2. Swelling: In the legs, ankles, and feet.
3. Nausea and vomiting: Due to the buildup of waste products in the body.
4. Poor appetite: Loss of interest in food.
5. Difficulty concentrating: Cognitive impairment due to the buildup of waste products in the brain.
6. Shortness of breath: Due to fluid buildup in the lungs.
7. Pain: In the back, flank, or abdomen.
8. Urination changes: Decreased urine production, dark-colored urine, or blood in the urine.
9. Heart problems: Chronic kidney failure can increase the risk of heart disease and heart attack.

Diagnosis:

Chronic kidney failure is typically diagnosed based on a combination of physical examination findings, medical history, laboratory tests, and imaging studies. Laboratory tests may include:

1. Blood urea nitrogen (BUN) and creatinine: Waste products in the blood that increase with decreased kidney function.
2. Electrolyte levels: Imbalances in electrolytes such as sodium, potassium, and phosphorus can indicate kidney dysfunction.
3. Kidney function tests: Measurement of glomerular filtration rate (GFR) to determine the level of kidney function.
4. Urinalysis: Examination of urine for protein, blood, or white blood cells.

Imaging studies may include:

1. Ultrasound: To assess the size and shape of the kidneys, detect any blockages, and identify any other abnormalities.
2. Computed tomography (CT) scan: To provide detailed images of the kidneys and detect any obstructions or abscesses.
3. Magnetic resonance imaging (MRI): To evaluate the kidneys and detect any damage or scarring.

Treatment:

Treatment for chronic kidney failure depends on the underlying cause and the severity of the disease. The goals of treatment are to slow progression of the disease, manage symptoms, and improve quality of life. Treatment may include:

1. Medications: To control high blood pressure, lower cholesterol levels, reduce proteinuria, and manage anemia.
2. Diet: A healthy diet that limits protein intake, controls salt and water intake, and emphasizes low-fat dairy products, fruits, and vegetables.
3. Fluid management: Monitoring and control of fluid intake to prevent fluid buildup in the body.
4. Dialysis: A machine that filters waste products from the blood when the kidneys are no longer able to do so.
5. Transplantation: A kidney transplant may be considered for some patients with advanced chronic kidney failure.

Complications:

Chronic kidney failure can lead to several complications, including:

1. Heart disease: High blood pressure and anemia can increase the risk of heart disease.
2. Anemia: A decrease in red blood cells can cause fatigue, weakness, and shortness of breath.
3. Bone disease: A disorder that can lead to bone pain, weakness, and an increased risk of fractures.
4. Electrolyte imbalance: Imbalances of electrolytes such as potassium, phosphorus, and sodium can cause muscle weakness, heart arrhythmias, and other complications.
5. Infections: A decrease in immune function can increase the risk of infections.
6. Nutritional deficiencies: Poor appetite, nausea, and vomiting can lead to malnutrition and nutrient deficiencies.
7. Cardiovascular disease: High blood pressure, anemia, and other complications can increase the risk of cardiovascular disease.
8. Pain: Chronic kidney failure can cause pain, particularly in the back, flank, and abdomen.
9. Sleep disorders: Insomnia, sleep apnea, and restless leg syndrome are common complications.
10. Depression and anxiety: The emotional burden of chronic kidney failure can lead to depression and anxiety.

In healthy individuals, the normal platelet count ranges from 150,000 to 450,000 platelets per microliter of blood. In thrombocytosis, the platelet count is significantly higher than this range, often above 600,000 platelets/μL.

Thrombocytosis can be caused by a variety of factors, including:

1. Bone marrow disorders: Disorders such as essential thrombocythemia, polycythemia vera, and myelofibrosis can lead to an overproduction of platelets in the bone marrow.
2. Infection: Sepsis and other infections can cause a temporary increase in platelet production.
3. Inflammation: Certain inflammatory conditions, such as appendicitis and pancreatitis, can also lead to thrombocytosis.
4. Cancer: Some types of cancer, such as leukemia and lymphoma, can cause an overproduction of platelets.
5. Medications: Certain medications, such as estrogens and corticosteroids, can increase platelet production.

Thrombocytosis can lead to a range of complications, including:

1. Blood clots: The excessive number of platelets in the blood can increase the risk of blood clots forming in the veins and arteries.
2. Pulmonary embolism: If a blood clot forms in the lungs, it can cause a pulmonary embolism, which can be life-threatening.
3. Stroke: Thrombocytosis can increase the risk of stroke, especially if there are existing risk factors such as high blood pressure or a history of cardiovascular disease.
4. Heart attack and heart failure: Excessive platelet activity can increase the risk of heart attack and heart failure.
5. Gastrointestinal bleeding: The increased number of platelets in the blood can make it more difficult to control bleeding, especially in the gastrointestinal tract.

Thrombocytosis is typically diagnosed through a combination of physical examination, medical history, and laboratory tests, such as:

1. Complete blood count (CBC): This test measures the number of platelets in the blood, as well as other components such as red and white blood cells.
2. Blood smear: A sample of blood is examined under a microscope to assess the shape and size of the platelets.
3. Bone marrow aspiration and biopsy: These tests involve removing a small sample of bone marrow tissue to examine the number and type of cells present.
4. Imaging studies: Imaging tests such as ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) may be used to look for evidence of blood clots or other complications.

Treatment for thrombocytosis depends on the underlying cause and the severity of the condition. Some common treatments include:

1. Medications: Drugs such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and blood thinners may be used to reduce the risk of blood clots and other complications.
2. Plateletpheresis: This is a procedure in which the patient's blood is removed and the platelets are separated from the rest of the blood components. The remaining blood is then returned to the body.
3. Splenectomy: In some cases, surgical removal of the spleen may be necessary to treat thrombocytosis.
4. Chemotherapy: This is a treatment that uses drugs to kill cancer cells, which can cause thrombocytosis in some cases.

Overall, it is important to seek medical attention if you experience any symptoms of thrombocytosis, as early diagnosis and treatment can help prevent complications and improve outcomes.

1. Anemia: Folic acid plays a critical role in the production of red blood cells, so a deficiency can lead to anemia, which can cause fatigue, weakness, and shortness of breath.
2. Birth defects: Folic acid is crucial for fetal development during pregnancy, and a deficiency can increase the risk of birth defects such as spina bifida and cleft palate.
3. Heart disease: Folic acid helps to regulate homocysteine levels in the blood, which are associated with an increased risk of heart disease and stroke.
4. Neurological problems: Folic acid is important for the health of the nervous system, and a deficiency can lead to neurological problems such as cognitive impairment, mood disturbances, and seizures.
5. Poor wound healing: Folic acid is necessary for the production of collagen, which is important for wound healing. A deficiency can lead to slow or poor wound healing.
6. Increased risk of cancer: Some studies suggest that a folic acid deficiency may increase the risk of certain types of cancer, such as colon cancer.
7. Hair loss: Folic acid is important for hair growth, and a deficiency can lead to hair loss.
8. Skin problems: Folic acid is important for skin health, and a deficiency can lead to skin problems such as dry, flaky skin and mouth sores.
9. Mood changes: Folic acid plays a role in the production of neurotransmitters, which are chemicals that regulate mood. A deficiency can lead to mood changes such as depression and anxiety.
10. Fatigue: Folic acid is important for energy metabolism, and a deficiency can lead to fatigue and weakness.

Folic acid deficiency can be caused by a number of factors, including:

1. Poor diet: A diet that is low in folate-rich foods can lead to a deficiency.
2. Malabsorption: Certain medical conditions such as celiac disease and Crohn's disease can lead to malabsorption of folic acid.
3. Pregnancy and lactation: Women who are pregnant or breastfeeding have a higher need for folic acid, and may be at risk for deficiency if they do not consume enough.
4. Alcoholism: Heavy alcohol consumption can interfere with the absorption of folic acid.
5. Certain medications: Some medications, such as antacids and proton pump inhibitors, can interfere with the absorption of folic acid.

To diagnose a folic acid deficiency, a healthcare provider may perform a physical exam, take a medical history, and order blood tests to measure folic acid levels. Treatment for a folic acid deficiency typically involves dietary changes and supplements. Dietary changes may include consuming more folate-rich foods, such as leafy green vegetables, legumes, and whole grains. Supplements may include folic acid tablets or liquid supplements. In severe cases of deficiency, injections of folic acid may be necessary. It is important to seek medical attention if you suspect a folic acid deficiency, as untreated deficiencies can lead to serious health problems.

Examples of acute diseases include:

1. Common cold and flu
2. Pneumonia and bronchitis
3. Appendicitis and other abdominal emergencies
4. Heart attacks and strokes
5. Asthma attacks and allergic reactions
6. Skin infections and cellulitis
7. Urinary tract infections
8. Sinusitis and meningitis
9. Gastroenteritis and food poisoning
10. Sprains, strains, and fractures.

Acute diseases can be treated effectively with antibiotics, medications, or other therapies. However, if left untreated, they can lead to chronic conditions or complications that may require long-term care. Therefore, it is important to seek medical attention promptly if symptoms persist or worsen over time.

There are several different types of leukemia, including:

1. Acute Lymphoblastic Leukemia (ALL): This is the most common type of leukemia in children, but it can also occur in adults. It is characterized by an overproduction of immature white blood cells called lymphoblasts.
2. Acute Myeloid Leukemia (AML): This type of leukemia affects the bone marrow's ability to produce red blood cells, platelets, and other white blood cells. It can occur at any age but is most common in adults.
3. Chronic Lymphocytic Leukemia (CLL): This type of leukemia affects older adults and is characterized by the slow growth of abnormal white blood cells called lymphocytes.
4. Chronic Myeloid Leukemia (CML): This type of leukemia is caused by a genetic mutation in a gene called BCR-ABL. It can occur at any age but is most common in adults.
5. Hairy Cell Leukemia: This is a rare type of leukemia that affects older adults and is characterized by the presence of abnormal white blood cells called hairy cells.
6. Myelodysplastic Syndrome (MDS): This is a group of disorders that occur when the bone marrow is unable to produce healthy blood cells. It can lead to leukemia if left untreated.

Treatment for leukemia depends on the type and severity of the disease, but may include chemotherapy, radiation therapy, targeted therapy, or stem cell transplantation.

1. Leukemia: A type of cancer that affects the blood and bone marrow, characterized by an overproduction of immature white blood cells.
2. Lymphoma: A type of cancer that affects the immune system, often involving the lymph nodes and other lymphoid tissues.
3. Multiple myeloma: A type of cancer that affects the plasma cells in the bone marrow, leading to an overproduction of abnormal plasma cells.
4. Myelodysplastic syndrome (MDS): A group of disorders characterized by the impaired development of blood cells in the bone marrow.
5. Osteopetrosis: A rare genetic disorder that causes an overgrowth of bone, leading to a thickened bone marrow.
6. Bone marrow failure: A condition where the bone marrow is unable to produce enough blood cells, leading to anemia, infection, and other complications.
7. Myelofibrosis: A condition characterized by the scarring of the bone marrow, which can lead to an overproduction of blood cells and an increased risk of bleeding and infection.
8. Polycythemia vera: A rare blood disorder that causes an overproduction of red blood cells, leading to an increased risk of blood clots and other complications.
9. Essential thrombocythemia: A rare blood disorder that causes an overproduction of platelets, leading to an increased risk of blood clots and other complications.
10. Myeloproliferative neoplasms (MPNs): A group of rare blood disorders that are characterized by the overproduction of blood cells and an increased risk of bleeding and infection.

These are just a few examples of bone marrow diseases. There are many other conditions that can affect the bone marrow, and each one can have a significant impact on a person's quality of life. If you suspect that you or someone you know may have a bone marrow disease, it is important to seek medical attention as soon as possible. A healthcare professional can perform tests and provide a proper diagnosis and treatment plan.

The main symptoms of PTI include:

* Purple spots or bruises (purpura) on the skin, which may be caused by minor trauma or injury.
* Thrombocytopenia (low platelet count), typically less than 50,000 platelets/mm3.
* Mild anemia and reticulocytosis (increased immature red blood cells).
* Elevated levels of autoantibodies against platelet membrane glycoproteins (GP) and other platelet proteins.
* No evidence of other causes of thrombocytopenia, such as bone marrow disorders or infections.

The exact cause of PTI is unknown, but it is believed to involve an immune-mediated response triggered by a genetic predisposition. Treatment options for PTI include corticosteroids, intravenous immunoglobulin (IVIG), and splenectomy in severe cases. The prognosis for PTI is generally good, with most patients experiencing resolution of symptoms and normalization of platelet counts within a few months to a year after treatment. However, some individuals may experience recurrent episodes of thrombocytopenia and purpura throughout their lives.

AML is a fast-growing and aggressive form of leukemia that can spread to other parts of the body through the bloodstream. It is most commonly seen in adults over the age of 60, but it can also occur in children.

There are several subtypes of AML, including:

1. Acute promyelocytic leukemia (APL): This is a subtype of AML that is characterized by the presence of a specific genetic abnormality called the PML-RARA fusion gene. It is usually responsive to treatment with chemotherapy and has a good prognosis.
2. Acute myeloid leukemia, not otherwise specified (NOS): This is the most common subtype of AML and does not have any specific genetic abnormalities. It can be more difficult to treat and has a poorer prognosis than other subtypes.
3. Chronic myelomonocytic leukemia (CMML): This is a subtype of AML that is characterized by the presence of too many immature white blood cells called monocytes in the blood and bone marrow. It can progress slowly over time and may require ongoing treatment.
4. Juvenile myeloid leukemia (JMML): This is a rare subtype of AML that occurs in children under the age of 18. It is characterized by the presence of too many immature white blood cells called blasts in the blood and bone marrow.

The symptoms of AML can vary depending on the subtype and the severity of the disease, but they may include:

* Fatigue
* Weakness
* Shortness of breath
* Pale skin
* Easy bruising or bleeding
* Swollen lymph nodes, liver, or spleen
* Bone pain
* Headache
* Confusion or seizures

AML is diagnosed through a combination of physical examination, medical history, and diagnostic tests such as:

1. Complete blood count (CBC): This test measures the number and types of cells in the blood, including red blood cells, white blood cells, and platelets.
2. Bone marrow biopsy: This test involves removing a small sample of bone marrow tissue from the hipbone or breastbone to examine under a microscope for signs of leukemia cells.
3. Genetic testing: This test can help identify specific genetic abnormalities that are associated with AML.
4. Immunophenotyping: This test uses antibodies to identify the surface proteins on leukemia cells, which can help diagnose the subtype of AML.
5. Cytogenetics: This test involves staining the bone marrow cells with dyes to look for specific changes in the chromosomes that are associated with AML.

Treatment for AML typically involves a combination of chemotherapy, targeted therapy, and in some cases, bone marrow transplantation. The specific treatment plan will depend on the subtype of AML, the patient's age and overall health, and other factors. Some common treatments for AML include:

1. Chemotherapy: This involves using drugs to kill cancer cells. The most commonly used chemotherapy drugs for AML are cytarabine (Ara-C) and anthracyclines such as daunorubicin (DaunoXome) and idarubicin (Idamycin).
2. Targeted therapy: This involves using drugs that specifically target the genetic abnormalities that are causing the cancer. Examples of targeted therapies used for AML include midostaurin (Rydapt) and gilteritinib (Xospata).
3. Bone marrow transplantation: This involves replacing the diseased bone marrow with healthy bone marrow from a donor. This is typically done after high-dose chemotherapy to destroy the cancer cells.
4. Supportive care: This includes treatments to manage symptoms and side effects of the disease and its treatment, such as anemia, infection, and bleeding. Examples of supportive care for AML include blood transfusions, antibiotics, and platelet transfusions.
5. Clinical trials: These are research studies that involve testing new treatments for AML. Participating in a clinical trial may give patients access to innovative therapies that are not yet widely available.

It's important to note that the treatment plan for AML is highly individualized, and the specific treatments used will depend on the patient's age, overall health, and other factors. Patients should work closely with their healthcare team to determine the best course of treatment for their specific needs.

There are several subtypes of MDS, each with distinct clinical features and prognosis. The most common subtype is refractory anemia with excess blasts (RAEB), followed by chronic myelomonocytic leukemia (CMMoL) and acute myeloid leukemia (AML).

The exact cause of MDS is not fully understood, but it is believed to result from a combination of genetic mutations and environmental factors. Risk factors for developing MDS include exposure to certain chemicals or radiation, age over 60, and a history of previous cancer treatment.

Symptoms of MDS can vary depending on the specific subtype and severity of the disorder, but may include fatigue, weakness, shortness of breath, infection, bleeding, and easy bruising. Diagnosis is typically made through a combination of physical examination, medical history, blood tests, and bone marrow biopsy.

Treatment for MDS depends on the specific subtype and severity of the disorder, as well as the patient's overall health and preferences. Options may include supportive care, such as blood transfusions and antibiotics, or more intensive therapies like chemotherapy, bone marrow transplantation, or gene therapy.

Overall, myelodysplastic syndromes are a complex and heterogeneous group of disorders that can have a significant impact on quality of life and survival. Ongoing research is focused on improving diagnostic accuracy, developing more effective treatments, and exploring novel therapeutic approaches to improve outcomes for patients with MDS.

Treatment options for ascites include medications to reduce fluid buildup, dietary restrictions, and insertion of a catheter to drain the fluid. In severe cases, a liver transplant may be necessary. It is important to seek medical attention if symptoms persist or worsen over time.

Ascites is a serious condition that requires ongoing management and monitoring to prevent complications and improve quality of life.

Disease progression can be classified into several types based on the pattern of worsening:

1. Chronic progressive disease: In this type, the disease worsens steadily over time, with a gradual increase in symptoms and decline in function. Examples include rheumatoid arthritis, osteoarthritis, and Parkinson's disease.
2. Acute progressive disease: This type of disease worsens rapidly over a short period, often followed by periods of stability. Examples include sepsis, acute myocardial infarction (heart attack), and stroke.
3. Cyclical disease: In this type, the disease follows a cycle of worsening and improvement, with periodic exacerbations and remissions. Examples include multiple sclerosis, lupus, and rheumatoid arthritis.
4. Recurrent disease: This type is characterized by episodes of worsening followed by periods of recovery. Examples include migraine headaches, asthma, and appendicitis.
5. Catastrophic disease: In this type, the disease progresses rapidly and unpredictably, with a poor prognosis. Examples include cancer, AIDS, and organ failure.

Disease progression can be influenced by various factors, including:

1. Genetics: Some diseases are inherited and may have a predetermined course of progression.
2. Lifestyle: Factors such as smoking, lack of exercise, and poor diet can contribute to disease progression.
3. Environmental factors: Exposure to toxins, allergens, and other environmental stressors can influence disease progression.
4. Medical treatment: The effectiveness of medical treatment can impact disease progression, either by slowing or halting the disease process or by causing unintended side effects.
5. Co-morbidities: The presence of multiple diseases or conditions can interact and affect each other's progression.

Understanding the type and factors influencing disease progression is essential for developing effective treatment plans and improving patient outcomes.

Sources:

1. Dictionary of Medical Microbiology, Second Edition. Edited by A. S. Chakrabarti and S. K. Das. Springer, 2012.
2. Medical Microbiology, Fourth Edition. Edited by P. R. Murray, K. S. N air, and M. J. Laurence. Mosby, 2014.

Symptoms of iron overload can include fatigue, weakness, joint pain, and abdominal discomfort. Treatment for iron overload usually involves reducing iron intake and undergoing regular phlebotomy (blood removal) to remove excess iron from the body. In severe cases, iron chelation therapy may be recommended to help remove excess iron from tissues and organs.

In addition to these medical definitions and treatments, there are also some key points to keep in mind when it comes to iron overload:

1. Iron is essential for human health, but too much of it can be harmful. The body needs a certain amount of iron to produce hemoglobin, the protein in red blood cells that carries oxygen throughout the body. However, excessive iron levels can damage organs and tissues.
2. Hereditary hemochromatosis is the most common cause of iron overload. This genetic disorder causes the body to absorb too much iron from food, leading to its accumulation in organs and tissues.
3. Iron overload can increase the risk of certain diseases, such as liver cirrhosis, diabetes, and heart disease. It can also lead to a condition called hemosiderosis, which is characterized by the deposition of iron in tissues and organs.
4. Phlebotomy is a safe and effective treatment for iron overload. Regular blood removal can help reduce excess iron levels and prevent complications such as liver damage, heart failure, and anemia.
5. Iron chelation therapy may be recommended in severe cases of iron overload. This involves using drugs to remove excess iron from tissues and organs, but it is not always necessary and can have potential side effects.

White blood cells are an important part of the immune system, and they help to fight off infections and diseases. A low number of white blood cells can make a person more susceptible to infections and other health problems.

There are several different types of leukopenia, including:

* Severe congenital neutropenia: This is a rare genetic disorder that causes a severe decrease in the number of neutrophils, a type of white blood cell.
* Chronic granulomatous disease: This is a genetic disorder that affects the production of white blood cells and can cause recurring infections.
* Autoimmune disorders: These are conditions where the immune system mistakenly attacks its own cells, including white blood cells. Examples include lupus and rheumatoid arthritis.
* Bone marrow failure: This is a condition where the bone marrow does not produce enough white blood cells, red blood cells, or platelets.

Symptoms of leukopenia can include recurring infections, fever, fatigue, and weight loss. Treatment depends on the underlying cause of the condition and may include antibiotics, immunoglobulin replacement therapy, or bone marrow transplantation.

1. Types of Hookworms: There are two main types of hookworms that can infect humans: Ancylostoma duodenale and Necator americanus. A. duodenale is more common in temperate climates, while N. americanus is found in tropical and subtropical regions.
2. Transmission: Hookworms are typically spread through contact with contaminated feces or soil. This can happen when someone ingests food or water that has been contaminated with hookworm eggs or larvae. In rare cases, hookworms can also be transmitted through blood transfusions or organ transplants.
3. Symptoms: The symptoms of hookworm infections can vary depending on the severity of the infection and the number of worms present. Common symptoms include diarrhea, abdominal pain, fatigue, weight loss, and anemia. In severe cases, hookworms can cause inflammation of the intestines, which can lead to complications such as bowel obstruction or perforation.
4. Diagnosis: Hookworm infections are typically diagnosed through a stool sample or blood test. A doctor may also perform a physical examination and take a medical history to help determine the presence of hookworms.
5. Treatment: Hookworm infections can be treated with antiparasitic medications, such as albendazole or mebendazole. These medications work by killing the worms in the intestines, which helps to relieve symptoms and prevent complications. In some cases, treatment may also involve addressing any underlying conditions that have been exacerbated by the hookworm infection, such as anemia or malnutrition.
6. Prevention: The best way to prevent hookworm infections is to practice good hygiene and avoid contact with contaminated feces or soil. This includes washing your hands frequently, especially after using the bathroom or before handling food. Additionally, wearing shoes when outdoors can help reduce the risk of contracting a hookworm infection through contact with contaminated soil.


The most common types of hemoglobinopathies include:

1. Sickle cell disease: This is caused by a point mutation in the HBB gene that codes for the beta-globin subunit of hemoglobin. It results in the production of sickle-shaped red blood cells, which can cause anemia, infections, and other complications.
2. Thalassemia: This is a group of genetic disorders that affect the production of hemoglobin and can result in anemia, fatigue, and other complications.
3. Hemophilia A: This is caused by a defect in the F8 gene that codes for coagulation factor VIII, which is essential for blood clotting. It can cause bleeding episodes, especially in males.
4. Glucose-6-phosphate dehydrogenase (G6PD) deficiency: This is caused by a point mutation in the G6PD gene that codes for an enzyme involved in red blood cell production. It can cause hemolytic anemia, especially in individuals who consume certain foods or medications.
5. Hereditary spherocytosis: This is caused by point mutations in the ANK1 or SPTA1 genes that code for proteins involved in red blood cell membrane structure. It can cause hemolytic anemia and other complications.

Hemoglobinopathies can be diagnosed through genetic testing, such as DNA sequencing or molecular genetic analysis. Treatment options vary depending on the specific disorder but may include blood transfusions, medications, and in some cases, bone marrow transplantation.

There are several risk factors for developing AF, including:

1. Age: The risk of developing AF increases with age, with the majority of cases occurring in people over the age of 65.
2. Hypertension (high blood pressure): High blood pressure can damage the heart and increase the risk of developing AF.
3. Heart disease: People with heart disease, such as coronary artery disease or heart failure, are at higher risk of developing AF.
4. Diabetes mellitus: Diabetes can increase the risk of developing AF.
5. Sleep apnea: Sleep apnea can increase the risk of developing AF.
6. Certain medications: Certain medications, such as thyroid medications and asthma medications, can increase the risk of developing AF.
7. Alcohol consumption: Excessive alcohol consumption has been linked to an increased risk of developing AF.
8. Smoking: Smoking is a risk factor for many cardiovascular conditions, including AF.
9. Obesity: Obesity is a risk factor for many cardiovascular conditions, including AF.

Symptoms of AF can include:

1. Palpitations (rapid or irregular heartbeat)
2. Shortness of breath
3. Fatigue
4. Dizziness or lightheadedness
5. Chest pain or discomfort

AF can be diagnosed with the help of several tests, including:

1. Electrocardiogram (ECG): This is a non-invasive test that measures the electrical activity of the heart.
2. Holter monitor: This is a portable device that records the heart's rhythm over a 24-hour period.
3. Event monitor: This is a portable device that records the heart's rhythm over a longer period of time, usually 1-2 weeks.
4. Echocardiogram: This is an imaging test that uses sound waves to create pictures of the heart.
5. Cardiac MRI: This is an imaging test that uses magnetic fields and radio waves to create detailed pictures of the heart.

Treatment for AF depends on the underlying cause and may include medications, such as:

1. Beta blockers: These medications slow the heart rate and reduce the force of the heart's contractions.
2. Antiarrhythmics: These medications help regulate the heart's rhythm.
3. Blood thinners: These medications prevent blood clots from forming and can help reduce the risk of stroke.
4. Calcium channel blockers: These medications slow the entry of calcium into the heart muscle cells, which can help slow the heart rate and reduce the force of the heart's contractions.

In some cases, catheter ablation may be recommended to destroy the abnormal electrical pathway causing AF. This is a minimally invasive procedure that involves inserting a catheter through a vein in the leg and guiding it to the heart using x-ray imaging. Once the catheter is in place, energy is applied to the abnormal electrical pathway to destroy it and restore a normal heart rhythm.

It's important to note that AF can increase the risk of stroke, so anticoagulation therapy may be recommended to reduce this risk. This can include medications such as warfarin or aspirin, or in some cases, implantable devices such as a left atrial appendage closure device.

In conclusion, atrial fibrillation is a common heart rhythm disorder that can increase the risk of stroke and heart failure. Treatment options depend on the underlying cause and may include medications, cardioversion, catheter ablation, or anticoagulation therapy. It's important to work closely with a healthcare provider to determine the best course of treatment for AF.

There are two main types of status epilepticus:

1. Generalized status epilepticus: This type affects the entire brain and is characterized by severe convulsions, loss of consciousness, and muscle stiffness.
2. Focal status epilepticus: This type affects only one part of the brain and can cause more subtle symptoms, such as weakness or numbness in a limb, speech difficulties, or confusion.

The diagnosis of status epilepticus is based on clinical findings, medical history, and electroencephalography (EEG) recordings. Treatment typically involves prompt administration of anticonvulsant medications, such as benzodiazepines or barbiturates, to control seizures and prevent further brain damage. In severe cases, sedation, mechanical ventilation, or anesthesia may be required to support the patient's vital functions.

The prognosis for status epilepticus depends on several factors, including the underlying cause, the severity of the seizure, and the promptness and effectiveness of treatment. In general, the earlier the treatment is initiated, the better the outcome. However, long-term neurological and cognitive deficits can occur in some cases.

Preventive measures for status epilepticus include proper management of underlying conditions that may trigger seizures, such as epilepsy or head trauma, and avoiding triggers like alcohol or drugs. Additionally, prompt medical attention should be sought if seizure warning signs are present, such as changes in sensation, confusion, or convulsions.

In medical terminology, nausea is sometimes used interchangeably with the term "dyspepsia," which refers to a general feeling of discomfort or unease in the stomach, often accompanied by symptoms such as bloating, belching, or heartburn. However, while nausea and dyspepsia can be related, they are not always the same thing, and it's important to understand the specific underlying cause of any gastrointestinal symptoms in order to provide appropriate treatment.

Some common causes of nausea include:

* Gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and gastritis
* Motion sickness or seasickness
* Medication side effects, including chemotherapy drugs, antibiotics, and painkillers
* Pregnancy and morning sickness
* Food poisoning or other infections
* Migraines and other headaches
* Anxiety and stress

Treatment for nausea will depend on the underlying cause, but may include medications such as antihistamines, anticholinergics, or anti-nausea drugs, as well as non-pharmacological interventions such as ginger, acupressure, or relaxation techniques. In severe cases, hospitalization may be necessary to manage symptoms and prevent dehydration or other complications.

In LLCB, the B cells undergo a mutation that causes them to become cancerous and multiply rapidly. This can lead to an overproduction of these cells in the bone marrow, causing the bone marrow to become crowded and unable to produce healthy red blood cells, platelets, and white blood cells.

LLCB is typically a slow-growing cancer, and it can take years for symptoms to develop. However, as the cancer progresses, it can lead to a range of symptoms including fatigue, weakness, weight loss, fever, night sweats, and swollen lymph nodes.

LLCB is typically diagnosed through a combination of physical examination, blood tests, bone marrow biopsy, and imaging studies such as X-rays or CT scans. Treatment options for LLCB include chemotherapy, radiation therapy, and in some cases, stem cell transplantation.

Overall, while LLCB is a serious condition, it is typically slow-growing and can be managed with appropriate treatment. With current treatments, many people with LLCB can achieve long-term remission and a good quality of life.

Falciparum malaria can cause a range of symptoms, including fever, chills, headache, muscle and joint pain, fatigue, nausea, and vomiting. In severe cases, the disease can lead to anemia, organ failure, and death.

Diagnosis of falciparum malaria typically involves a physical examination, medical history, and laboratory tests to detect the presence of parasites in the blood or other bodily fluids. Treatment usually involves the use of antimalarial drugs, such as artemisinin-based combination therapies (ACTs) or quinine, which can effectively cure the disease if administered promptly.

Prevention of falciparum malaria is critical to reducing the risk of infection, and this includes the use of insecticide-treated bed nets, indoor residual spraying (IRS), and preventive medications for travelers to high-risk areas. Eliminating standing water around homes and communities can also help reduce the number of mosquitoes and the spread of the disease.

In summary, falciparum malaria is a severe and life-threatening form of malaria caused by the Plasmodium falciparum parasite, which is responsible for the majority of malaria-related deaths worldwide. Prompt diagnosis and treatment are essential to prevent complications and death from this disease. Prevention measures include the use of bed nets, indoor spraying, and preventive medications, as well as reducing standing water around homes and communities.

There are two main forms of alpha-Thalassemia:

1. Alpha-thalassemia major (also known as Hemoglobin Bart's hydrops fetalis): This is a severe form of the disorder that can cause severe anemia, enlarged spleen, and death in infancy. It is caused by a complete absence of one or both of the HBA1 or HBA2 genes.
2. Alpha-thalassemia minor (also known as Hemoglobin carrier state): This form of the disorder is milder and may not cause any symptoms at all. It is caused by a partial deletion of one or both of the HBA1 or HBA2 genes.

People with alpha-thalassemia minor may have slightly lower levels of hemoglobin and may be more susceptible to anemia, but they do not typically experience any severe symptoms. Those with alpha-thalassemia major, on the other hand, are at risk for serious complications such as anemia, infections, and organ failure.

There is no cure for alpha-thalassemia, but treatment options include blood transfusions, iron chelation therapy, and management of associated complications. Screening for alpha-thalassemia is recommended for individuals who are carriers of the disorder, as well as for those who have a family history of the condition.

Also known as: Hereditary spherocytosis (HSS)

Previous article Sphenoid sinus
Next article Splenic infarction

Isoimmunization is a condition that occurs when an individual has antibodies against their own red blood cell antigens, specifically the Rh antigen. This can happen due to various reasons such as:

1. Incompatibility between the mother's and father's Rh antigens, leading to the development of antibodies in the mother during pregnancy or childbirth.
2. Blood transfusions from an incompatible donor.
3. Certain medical conditions like autoimmune hemolytic anemia or bone marrow transplantation.

Rh isoimmunization can lead to a range of complications, including:

1. Hemolytic disease of the newborn: This is a condition where the baby's red blood cells are destroyed by the mother's antibodies, leading to anemia, jaundice, and other serious complications.
2. Rh hemolytic crisis: This is a severe and potentially life-threatening complication that can occur during pregnancy or childbirth.
3. Chronic hemolytic anemia: This is a condition where the red blood cells are continuously destroyed, leading to anemia and other complications.

Rh isoimmunization can be diagnosed through blood tests such as the direct antiglobulin test (DAT) or the indirect Coombs test (ICT). Treatment typically involves managing any underlying conditions and monitoring for complications. In severe cases, a bone marrow transplant may be necessary. Prevention is key, and women who are Rh-negative should receive an injection of Rh immune globulin during pregnancy to prevent the development of antibodies against the Rh antigen.

The disorder is caused by mutations in the HBB gene that codes for the beta-globin subunit of hemoglobin. These mutations result in the production of abnormal hemoglobins that are unstable and prone to breakdown, leading to the release of free hemoglobin into the urine.

HP is classified into two types based on the severity of symptoms:

1. Type 1 HP: This is the most common form of the disorder and is characterized by mild to moderate anemia, occasional hemoglobinuria, and a normal life expectancy.
2. Type 2 HP: This is a more severe form of the disorder and is characterized by severe anemia, recurrent hemoglobinuria, and a shorter life expectancy.

There is no cure for HP, but treatment options are available to manage symptoms and prevent complications. These may include blood transfusions, folic acid supplements, and medications to reduce the frequency and severity of hemoglobinuria episodes.

There are two main types of hemolysis:

1. Intravascular hemolysis: This type occurs within the blood vessels and is caused by factors such as mechanical injury, oxidative stress, and certain infections.
2. Extravascular hemolysis: This type occurs outside the blood vessels and is caused by factors such as bone marrow disorders, splenic rupture, and certain medications.

Hemolytic anemia is a condition that occurs when there is excessive hemolysis of RBCs, leading to a decrease in the number of healthy red blood cells in the body. This can cause symptoms such as fatigue, weakness, pale skin, and shortness of breath.

Some common causes of hemolysis include:

1. Genetic disorders such as sickle cell anemia and thalassemia.
2. Autoimmune disorders such as autoimmune hemolytic anemia (AIHA).
3. Infections such as malaria, babesiosis, and toxoplasmosis.
4. Medications such as antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and blood thinners.
5. Bone marrow disorders such as aplastic anemia and myelofibrosis.
6. Splenic rupture or surgical removal of the spleen.
7. Mechanical injury to the blood vessels.

Diagnosis of hemolysis is based on a combination of physical examination, medical history, and laboratory tests such as complete blood count (CBC), blood smear examination, and direct Coombs test. Treatment depends on the underlying cause and may include supportive care, blood transfusions, and medications to suppress the immune system or prevent infection.

Myeloid leukemia can be classified into several subtypes based on the type of cell involved and the degree of maturity of the abnormal cells. The most common types of myeloid leukemia include:

1. Acute Myeloid Leukemia (AML): This is the most aggressive form of myeloid leukemia, characterized by a rapid progression of immature cells that do not mature or differentiate into normal cells. AML can be further divided into several subtypes based on the presence of certain genetic mutations or chromosomal abnormalities.
2. Chronic Myeloid Leukemia (CML): This is a slower-growing form of myeloid leukemia, characterized by the presence of a genetic abnormality known as the Philadelphia chromosome. CML is typically treated with targeted therapies or bone marrow transplantation.
3. Myelodysplastic Syndrome (MDS): This is a group of disorders characterized by the impaired development of immature blood cells in the bone marrow. MDS can progress to AML if left untreated.
4. Chronic Myelomonocytic Leukemia (CMML): This is a rare form of myeloid leukemia that is characterized by the accumulation of immature monocytes in the blood and bone marrow. CMML can be treated with chemotherapy or bone marrow transplantation.

The symptoms of myeloid leukemia can vary depending on the subtype and severity of the disease. Common symptoms include fatigue, weakness, fever, night sweats, and weight loss. Diagnosis is typically made through a combination of physical examination, blood tests, and bone marrow biopsy. Treatment options for myeloid leukemia can include chemotherapy, targeted therapies, bone marrow transplantation, and supportive care to manage symptoms and prevent complications. The prognosis for myeloid leukemia varies depending on the subtype of the disease and the patient's overall health. With current treatments, many patients with myeloid leukemia can achieve long-term remission or even be cured.

Examples of pregnancy complications, parasitic include:

1. Toxoplasmosis: This is a condition caused by the Toxoplasma gondii parasite, which can infect the mother and/or the fetus during pregnancy. Symptoms include fever, headache, and fatigue. In severe cases, toxoplasmosis can cause birth defects, such as intellectual disability, blindness, and deafness.
2. Malaria: This is a condition caused by the Plasmodium spp. parasite, which can be transmitted to the mother and/or the fetus during pregnancy. Symptoms include fever, chills, and flu-like symptoms. In severe cases, malaria can cause anemia, organ failure, and death.
3. Schistosomiasis: This is a condition caused by the Schistosoma spp. parasite, which can infect the mother and/or the fetus during pregnancy. Symptoms include abdominal pain, diarrhea, and fatigue. In severe cases, schistosomiasis can cause organ damage and infertility.

Pregnancy complications, parasitic can be diagnosed through blood tests, imaging studies, and other medical procedures. Treatment depends on the type of parasite and the severity of the infection. In some cases, treatment may involve antibiotics, antimalarial drugs, or anti-parasitic medications.

Preventive measures for pregnancy complications, parasitic include:

1. Avoiding contact with cat feces, as Toxoplasma gondii can be transmitted through contaminated soil and food.
2. Avoiding travel to areas where malaria and other parasitic infections are common.
3. Taking antimalarial medications before and during pregnancy if living in an area where malaria is common.
4. Using insecticide-treated bed nets and wearing protective clothing to prevent mosquito bites.
5. Practicing good hygiene, such as washing hands regularly, especially after handling food or coming into contact with cats.
6. Avoiding drinking unpasteurized dairy products and undercooked meat, as these can increase the risk of infection.
7. Ensuring that any water used for cooking or drinking is safe and free from parasites.

Preventive measures for pregnancy complications, parasitic are important for women who are pregnant or planning to become pregnant, as well as for their partners and healthcare providers. By taking these preventive measures, the risk of infection and complications can be significantly reduced.

In conclusion, pregnancy complications, parasitic are a serious issue that can have severe consequences for both the mother and the fetus. However, by understanding the causes, risk factors, symptoms, diagnosis, treatment, and preventive measures, women can take steps to protect themselves and their unborn babies from these infections. It is important for healthcare providers to be aware of these issues and provide appropriate education and care to pregnant women to reduce the risk of complications.

FAQs
1. What are some common parasitic infections that can occur during pregnancy?
Ans: Some common parasitic infections that can occur during pregnancy include malaria, toxoplasmosis, and cytomegalovirus (CMV).
2. How do parasitic infections during pregnancy affect the baby?
Ans: Parasitic infections during pregnancy can have serious consequences for the developing fetus, including birth defects, growth restriction, and stillbirth.
3. Can parasitic infections during pregnancy be treated?
Ans: Yes, parasitic infections during pregnancy can be treated with antibiotics and other medications. Early detection and treatment are important to prevent complications.
4. How can I prevent parasitic infections during pregnancy?
Ans: Preventive measures include avoiding areas where parasites are common, using insect repellents, wearing protective clothing, and practicing good hygiene. Pregnant women should also avoid undercooked meat and unpasteurized dairy products.
5. Do all pregnant women need to be tested for parasitic infections?
Ans: No, not all pregnant women need to be tested for parasitic infections. However, certain groups of women, such as those who live in areas where parasites are common or have a history of previous parasitic infections, may need to be tested and monitored more closely.
6. Can I prevent my baby from getting a parasitic infection during pregnancy?
Ans: Yes, there are several steps you can take to reduce the risk of your baby getting a parasitic infection during pregnancy, such as avoiding certain foods and taking antibiotics if necessary. Your healthcare provider can provide guidance on how to prevent and treat parasitic infections during pregnancy.
7. How are parasitic infections diagnosed during pregnancy?
Ans: Parasitic infections can be diagnosed through blood tests, stool samples, or imaging tests such as ultrasound or MRI. Your healthcare provider may also perform a physical exam and take a medical history to determine the likelihood of a parasitic infection.
8. Can parasitic infections cause long-term health problems for my baby?
Ans: Yes, some parasitic infections can cause long-term health problems for your baby, such as developmental delays or learning disabilities. In rare cases, parasitic infections can also lead to more serious complications, such as organ damage or death.
9. How are parasitic infections treated during pregnancy?
Ans: Treatment for parasitic infections during pregnancy may involve antibiotics, antiparasitic medications, or other supportive care. Your healthcare provider will determine the best course of treatment based on the severity and type of infection, as well as your individual circumstances.
10. Can I take steps to prevent parasitic infections during pregnancy?
Ans: Yes, there are several steps you can take to prevent parasitic infections during pregnancy, such as avoiding undercooked meat and fish, washing fruits and vegetables thoroughly, and practicing good hygiene. Additionally, if you have a higher risk of parasitic infections due to travel or other factors, your healthcare provider may recommend preventative medications or screening tests.
11. I'm pregnant and have been exposed to a parasitic infection. What should I do?
Ans: If you suspect that you have been exposed to a parasitic infection during pregnancy, it is important to seek medical attention immediately. Your healthcare provider can perform tests to determine if you have an infection and provide appropriate treatment to prevent any potential complications for your baby.
12. Can I breastfeed while taking medication for a parasitic infection?
Ans: It may be safe to breastfeed while taking medication for a parasitic infection, but it is important to consult with your healthcare provider before doing so. Some medications may not be safe for your baby and could potentially be passed through your milk. Your healthcare provider can provide guidance on the safest treatment options for you and your baby.
13. What are some common complications of parasitic infections during pregnancy?
Ans: Complications of parasitic infections during pregnancy can include miscarriage, preterm labor, low birth weight, and congenital anomalies. In rare cases, parasitic infections can also be transmitted to the baby during pregnancy or childbirth, which can lead to serious health problems for the baby.
14. Can I get a parasitic infection from my pet?
Ans: Yes, it is possible to get a parasitic infection from your pet if you come into contact with their feces or other bodily fluids. For example, toxoplasmosis can be transmitted through contact with cat feces, while hookworm infections can be spread through contact with contaminated soil or feces. It is important to practice good hygiene and take precautions when handling pets or coming into contact with potentially contaminated areas.
15. How can I prevent parasitic infections?
Ans: Preventing parasitic infections involves taking steps to avoid exposure to parasites and their vectors, as well as practicing good hygiene and taking precautions when traveling or engaging in activities that may put you at risk. Some ways to prevent parasitic infections include:
* Avoiding undercooked meat, especially pork and wild game
* Avoiding raw or unpasteurized dairy products
* Avoiding contaminated water and food
* Washing your hands frequently, especially after using the bathroom or before handling food
* Avoiding contact with cat feces, as toxoplasmosis can be transmitted through contact with cat feces
* Using protective clothing and insect repellent when outdoors in areas where parasites are common
* Keeping your home clean and free of clutter to reduce the risk of parasite infestations
* Avoiding touching or eating wild animals or plants that may be contaminated with parasites
16. What are some common misconceptions about parasitic infections?
Ans: There are several common misconceptions about parasitic infections, including:
* All parasites are the same and have similar symptoms
* Parasitic infections are only a problem for people who live in developing countries or have poor hygiene
* Only certain groups of people, such as children or pregnant women, are at risk for parasitic infections
* Parasitic infections are rare in developed countries
* All parasites can be treated with antibiotics
* Parasitic infections are not serious and do not require medical attention
17. How can I diagnose a parasitic infection?
Ans: Diagnosing a parasitic infection typically involves a combination of physical examination, medical history, and laboratory tests. Some common methods for diagnosing parasitic infections include:
* Physical examination to look for signs such as skin lesions or abdominal pain
* Blood tests to check for the presence of parasites or their waste products
* Stool tests to detect the presence of parasite eggs or larvae
* Imaging tests, such as X-rays or CT scans, to look for signs of parasite infection in internal organs
* Endoscopy, which involves inserting a flexible tube with a camera into the body to visualize the inside of the digestive tract and other organs.
18. How are parasitic infections treated?
Ans: Treatment for parasitic infections depends on the type of parasite and the severity of the infection. Some common methods for treating parasitic infections include:
* Antiparasitic drugs, such as antibiotics or antimalarials, to kill the parasites
* Supportive care, such as fluids and electrolytes, to manage symptoms and prevent complications
* Surgery to remove parasites or repair damaged tissues
* Antibiotics to treat secondary bacterial infections that may have developed as a result of the parasitic infection.
It is important to seek medical attention if you suspect that you have a parasitic infection, as untreated infections can lead to serious complications and can be difficult to diagnose.
19. How can I prevent parasitic infections?
Ans: Preventing parasitic infections involves taking steps to avoid contact with parasites and their vectors, as well as maintaining good hygiene practices. Some ways to prevent parasitic infections include:
* Avoiding undercooked meat and unpasteurized dairy products, which can contain harmful parasites such as Trichinella spiralis and Toxoplasma gondii
* Washing your hands frequently, especially after using the bathroom or before eating
* Avoiding contact with contaminated water or soil, which can harbor parasites such as Giardia and Cryptosporidium
* Using insecticides and repellents to prevent mosquito bites, which can transmit diseases such as malaria and dengue fever
* Wearing protective clothing and applying insect repellent when outdoors in areas where ticks and other vectors are common
* Avoiding contact with animals that may carry parasites, such as dogs and cats that can transmit Toxoplasma gondii
* Using clean water and proper sanitation to prevent the spread of parasitic infections in communities and developing countries.
It is also important to be aware of the risks of parasitic infections when traveling to areas where they are common, and to take appropriate precautions such as avoiding undercooked meat and unpasteurized dairy products, and using insecticides and repellents to prevent mosquito bites.
20. What is the prognosis for parasitic infections?
Ans: The prognosis for parasitic infections varies depending on the specific type of infection and the severity of symptoms. Some parasitic infections can be easily treated with antiparasitic medications, while others may require more extensive treatment and management.
In general, the prognosis for parasitic infections is good if the infection is detected early and properly treated. However, some parasitic infections can cause long-term health problems or death if left untreated. It is important to seek medical attention if symptoms persist or worsen over time.
It is also important to note that some parasitic infections can be prevented through public health measures such as using clean water and proper sanitation, and controlling the spread of insect vectors. Prevention is key to avoiding the negative outcomes associated with these types of infections.
21. What are some common complications of parasitic infections?
Ans: Some common complications of parasitic infections include:
* Anemia and other blood disorders, such as thrombocytopenia and leukopenia
* Allergic reactions to parasite antigens
* Inflammation and damage to organs and tissues, such as the liver, kidneys, and brain
* Increased risk of infections with other microorganisms, such as bacteria and viruses
* Malnutrition and deficiencies in essential nutrients
* Organ failure and death.
22. Can parasitic infections be prevented? If so, how?
Ans: Yes, some parasitic infections can be prevented through public health measures such as:
* Using clean water and proper sanitation to reduce the risk of ingesting infected parasites.
* Avoiding contact with insect vectors, such as mosquitoes and ticks, by using repellents, wearing protective clothing, and staying indoors during peak biting hours.
* Properly cooking and storing food to kill parasites that may be present.
* Avoiding consuming undercooked or raw meat, especially pork and wild game.
* Practicing safe sex to prevent the transmission of parasitic infections through sexual contact.
* Keeping children away from areas where they may come into contact with contaminated soil or water.
* Using antiparasitic drugs and other treatments as recommended by healthcare providers.
* Implementing control measures for insect vectors, such as spraying insecticides and removing breeding sites.
30. Can parasitic infections be treated with antibiotics? If so, which ones and why?
Ans: No, antibiotics are not effective against parasitic infections caused by protozoa, such as giardiasis and amoebiasis, because these organisms are not bacteria. However, antibiotics may be used to treat secondary bacterial infections that can develop as a complication of parasitic infections.
32. What is the difference between a parasite and a pathogen?
Ans: A parasite is an organism that lives on or in another organism, called the host, and feeds on the host's tissues or fluids without providing any benefits. A pathogen, on the other hand, is an organism that causes disease. While all parasites are pathogens, not all pathogens are parasites. For example, bacteria and viruses can cause diseases but are not considered parasites because they do not live within the host's body.

Examples of syndromes include:

1. Down syndrome: A genetic disorder caused by an extra copy of chromosome 21 that affects intellectual and physical development.
2. Turner syndrome: A genetic disorder caused by a missing or partially deleted X chromosome that affects physical growth and development in females.
3. Marfan syndrome: A genetic disorder affecting the body's connective tissue, causing tall stature, long limbs, and cardiovascular problems.
4. Alzheimer's disease: A neurodegenerative disorder characterized by memory loss, confusion, and changes in personality and behavior.
5. Parkinson's disease: A neurological disorder characterized by tremors, rigidity, and difficulty with movement.
6. Klinefelter syndrome: A genetic disorder caused by an extra X chromosome in males, leading to infertility and other physical characteristics.
7. Williams syndrome: A rare genetic disorder caused by a deletion of genetic material on chromosome 7, characterized by cardiovascular problems, developmental delays, and a distinctive facial appearance.
8. Fragile X syndrome: The most common form of inherited intellectual disability, caused by an expansion of a specific gene on the X chromosome.
9. Prader-Willi syndrome: A genetic disorder caused by a defect in the hypothalamus, leading to problems with appetite regulation and obesity.
10. Sjogren's syndrome: An autoimmune disorder that affects the glands that produce tears and saliva, causing dry eyes and mouth.

Syndromes can be diagnosed through a combination of physical examination, medical history, laboratory tests, and imaging studies. Treatment for a syndrome depends on the underlying cause and the specific symptoms and signs presented by the patient.

People with pica may eat these items in secret and experience a sense of relief or satisfaction after consuming them. The condition is more common in children and adolescents, but it can also affect adults. Pica can lead to nutritional deficiencies, gastrointestinal problems, and other health issues if the eaten items are not digestible or contain harmful substances.

Treatment for pica usually involves addressing any underlying mental health issues and providing education on nutrition and healthy eating habits. In some cases, medication may be prescribed to help manage symptoms. It is important to seek medical attention if you or someone you know is experiencing symptoms of pica, as early intervention can help prevent complications and improve overall health.

There are two main types of heart failure:

1. Left-sided heart failure: This occurs when the left ventricle, which is the main pumping chamber of the heart, becomes weakened and is unable to pump blood effectively. This can lead to congestion in the lungs and other organs.
2. Right-sided heart failure: This occurs when the right ventricle, which pumps blood to the lungs, becomes weakened and is unable to pump blood effectively. This can lead to congestion in the body's tissues and organs.

Symptoms of heart failure may include:

* Shortness of breath
* Fatigue
* Swelling in the legs, ankles, and feet
* Swelling in the abdomen
* Weight gain
* Coughing up pink, frothy fluid
* Rapid or irregular heartbeat
* Dizziness or lightheadedness

Treatment for heart failure typically involves a combination of medications and lifestyle changes. Medications may include diuretics to remove excess fluid from the body, ACE inhibitors or beta blockers to reduce blood pressure and improve blood flow, and aldosterone antagonists to reduce the amount of fluid in the body. Lifestyle changes may include a healthy diet, regular exercise, and stress reduction techniques. In severe cases, heart failure may require hospitalization or implantation of a device such as an implantable cardioverter-defibrillator (ICD) or a left ventricular assist device (LVAD).

It is important to note that heart failure is a chronic condition, and it requires ongoing management and monitoring to prevent complications and improve quality of life. With proper treatment and lifestyle changes, many people with heart failure are able to manage their symptoms and lead active lives.

The primary symptoms of celiac disease include diarrhea, abdominal pain, fatigue, weight loss, and bloating. However, some people may not experience any symptoms at all, but can still develop complications if the disease is left untreated. These complications can include malnutrition, anemia, osteoporosis, and increased risk of other autoimmune disorders.

The exact cause of celiac disease is unknown, but it is believed to be triggered by a combination of genetic and environmental factors. The disease is more common in people with a family history of celiac disease or other autoimmune disorders. Diagnosis is typically made through a combination of blood tests and intestinal biopsy, and treatment involves a strict gluten-free diet.

Dietary management of celiac disease involves avoiding all sources of gluten, including wheat, barley, rye, and some processed foods that may contain hidden sources of these grains. In some cases, nutritional supplements may be necessary to ensure adequate intake of certain vitamins and minerals.

While there is no known cure for celiac disease, adherence to a strict gluten-free diet can effectively manage the condition and prevent long-term complications. With proper management, people with celiac disease can lead normal, healthy lives.

The most common parvoviridae infection in animals is feline panleukopenia (FPV) or canine parvovirus (CPV), which affects dogs and cats. These infections are highly contagious and can cause a range of symptoms, including fever, vomiting, diarrhea, lethargy, and loss of appetite. In severe cases, they can lead to life-threatening complications such as anemia, bone marrow failure, and death.

There is no specific treatment for parvoviridae infections, but supportive care such as fluid therapy, antibiotics, and anti-inflammatory medication can help manage symptoms and prevent complications. Vaccination is the most effective way to prevent parvoviridae infections, and vaccines are available for dogs, cats, and other animals.

In humans, parvoviridae infections are rare but can occur through contact with infected animals or contaminated feces. The most common human parvoviridae infection is erythema infectiosum (Fifth disease), which causes a rash, fever, and mild symptoms. Pregnant women who contract parvoviridae infections may experience complications such as miscarriage or preterm labor. There is no specific treatment for human parvoviridae infections, but supportive care can help manage symptoms.

1) They share similarities with humans: Many animal species share similar biological and physiological characteristics with humans, making them useful for studying human diseases. For example, mice and rats are often used to study diseases such as diabetes, heart disease, and cancer because they have similar metabolic and cardiovascular systems to humans.

2) They can be genetically manipulated: Animal disease models can be genetically engineered to develop specific diseases or to model human genetic disorders. This allows researchers to study the progression of the disease and test potential treatments in a controlled environment.

3) They can be used to test drugs and therapies: Before new drugs or therapies are tested in humans, they are often first tested in animal models of disease. This allows researchers to assess the safety and efficacy of the treatment before moving on to human clinical trials.

4) They can provide insights into disease mechanisms: Studying disease models in animals can provide valuable insights into the underlying mechanisms of a particular disease. This information can then be used to develop new treatments or improve existing ones.

5) Reduces the need for human testing: Using animal disease models reduces the need for human testing, which can be time-consuming, expensive, and ethically challenging. However, it is important to note that animal models are not perfect substitutes for human subjects, and results obtained from animal studies may not always translate to humans.

6) They can be used to study infectious diseases: Animal disease models can be used to study infectious diseases such as HIV, TB, and malaria. These models allow researchers to understand how the disease is transmitted, how it progresses, and how it responds to treatment.

7) They can be used to study complex diseases: Animal disease models can be used to study complex diseases such as cancer, diabetes, and heart disease. These models allow researchers to understand the underlying mechanisms of the disease and test potential treatments.

8) They are cost-effective: Animal disease models are often less expensive than human clinical trials, making them a cost-effective way to conduct research.

9) They can be used to study drug delivery: Animal disease models can be used to study drug delivery and pharmacokinetics, which is important for developing new drugs and drug delivery systems.

10) They can be used to study aging: Animal disease models can be used to study the aging process and age-related diseases such as Alzheimer's and Parkinson's. This allows researchers to understand how aging contributes to disease and develop potential treatments.

The severity of GIH can vary widely, ranging from mild to life-threatening. Mild cases may resolve on their own or with minimal treatment, while severe cases may require urgent medical attention and aggressive intervention.

Gastrointestinal Hemorrhage Symptoms:

* Vomiting blood or passing black tarry stools
* Hematemesis (vomiting blood)
* Melena (passing black, tarry stools)
* Rectal bleeding
* Abdominal pain
* Fever
* Weakness and dizziness

Gastrointestinal Hemorrhage Causes:

* Peptic ulcers
* Gastroesophageal reflux disease (GERD)
* Inflammatory bowel disease (IBD)
* Diverticulosis and diverticulitis
* Cancer of the stomach, small intestine, or large intestine
* Vascular malformations

Gastrointestinal Hemorrhage Diagnosis:

* Physical examination
* Medical history
* Laboratory tests (such as complete blood count and coagulation studies)
* Endoscopy (to visualize the inside of the gastrointestinal tract)
* Imaging studies (such as X-rays, CT scans, or MRI)

Gastrointestinal Hemorrhage Treatment:

* Medications to control bleeding and reduce acid production in the stomach
* Endoscopy to locate and treat the site of bleeding
* Surgery to repair damaged blood vessels or remove a bleeding tumor
* Blood transfusions to replace lost blood

Gastrointestinal Hemorrhage Prevention:

* Avoiding alcohol and spicy foods
* Taking medications as directed to control acid reflux and other gastrointestinal conditions
* Maintaining a healthy diet and lifestyle
* Reducing stress
* Avoiding smoking and excessive caffeine consumption.

1. Protein-energy malnutrition (PEM): This type of malnutrition is caused by a lack of protein and energy in the diet. It is common in developing countries and can lead to weight loss, weakness, and stunted growth in children.
2. Iron deficiency anemia: This type of malnutrition is caused by a lack of iron in the diet, which is necessary for the production of hemoglobin in red blood cells. Symptoms include fatigue, weakness, and shortness of breath.
3. Vitamin and mineral deficiencies: Malnutrition can also be caused by a lack of essential vitamins and minerals such as vitamin A, vitamin D, calcium, and iodine. Symptoms vary depending on the specific deficiency but can include skin problems, impaired immune function, and poor wound healing.
4. Obesity: This type of malnutrition is caused by consuming too many calories and not enough nutrients. It can lead to a range of health problems including diabetes, high blood pressure, and heart disease.

Signs and symptoms of malnutrition can include:

* Weight loss or weight gain
* Fatigue or weakness
* Poor wound healing
* Hair loss
* Skin problems
* Increased infections
* Poor appetite or overeating
* Digestive problems such as diarrhea or constipation
* Impaired immune function

Treatment for malnutrition depends on the underlying cause and may include:

* Dietary changes: Eating a balanced diet that includes a variety of nutrient-rich foods can help to correct nutrient deficiencies.
* Nutritional supplements: In some cases, nutritional supplements such as vitamins or minerals may be recommended to help address specific deficiencies.
* Medical treatment: Certain medical conditions that contribute to malnutrition, such as digestive disorders or infections, may require treatment with medication or other interventions.

Prevention is key, and there are several steps you can take to help prevent malnutrition:

* Eat a balanced diet that includes a variety of nutrient-rich foods.
* Avoid restrictive diets or fad diets that limit specific food groups.
* Stay hydrated by drinking plenty of water.
* Avoid excessive alcohol consumption, which can interfere with nutrient absorption and lead to malnutrition.
* Maintain a healthy weight through a combination of a balanced diet and regular exercise.

It is important to note that malnutrition can be subtle and may not always be easily recognizable. If you suspect you or someone you know may be experiencing malnutrition, it is important to seek medical attention to receive an accurate diagnosis and appropriate treatment.

Epilepsy, temporal lobe can cause a variety of seizure types, including:

1. Partial seizures: These are seizures that affect only one part of the brain, such as the temporal lobe.
2. Simple partial seizures: These are seizures that do not involve convulsions or loss of consciousness.
3. Complex partial seizures: These are seizures that involve impaired awareness or altered perception, and may involve convulsions or muscle stiffness.
4. Tonic-clonic seizures (formerly known as grand mal seizures): These are seizures that involve convulsions, loss of consciousness, and muscle stiffness.

The symptoms of epilepsy, temporal lobe can vary depending on the location of the seizure focus within the temporal lobe and the individual's age, but may include:

1. Auras (sensory disturbances such as flashing lights or unusual smells)
2. Confusion or disorientation
3. Memory loss or difficulty with memory
4. Emotional changes (such as fear, anxiety, or euphoria)
5. Speech difficulties
6. Muscle stiffness or weakness
7. Coordination problems
8. Vision changes (such as blurred vision or double vision)
9. Hearing changes (such as ringing in the ears)
10. Numbness or tingling sensations

Epilepsy, temporal lobe is typically diagnosed using a combination of medical history, physical examination, and diagnostic tests such as electroencephalography (EEG) or magnetic resonance imaging (MRI). Treatment options may include medication, surgery, or lifestyle modifications.

The condition is inherited in an X-linked recessive pattern, meaning that the gene for G6PD deficiency is located on the X chromosome and affects males more frequently than females. Females may also be affected but typically have milder symptoms or may be carriers of the condition without experiencing any symptoms themselves.

G6PD deficiency can be caused by mutations in the G6PD gene, which can lead to a reduction in the amount of functional enzyme produced. The severity of the condition depends on the specific nature of the mutation and the degree to which it reduces the activity of the enzyme.

Symptoms of G6PD deficiency may include jaundice (yellowing of the skin and eyes), fatigue, weakness, and shortness of breath. In severe cases, the condition can lead to hemolytic anemia, which is characterized by the premature destruction of red blood cells. This can be triggered by certain drugs, infections, or foods that contain high levels of oxalic acid or other oxidizing agents.

Diagnosis of G6PD deficiency typically involves a combination of clinical evaluation, laboratory tests, and genetic analysis. Treatment is focused on managing symptoms and preventing complications through dietary modifications, medications, and avoidance of triggers such as certain drugs or infections.

Overall, G6PD deficiency is a relatively common genetic disorder that can have significant health implications if left untreated. Understanding the causes, symptoms, and treatment options for this condition is important for ensuring appropriate care and management for individuals affected by it.

The term "reticulocytosis" is derived from the Latin words "reticulum," meaning net-like, and "cytosis," meaning the condition of cells. This refers to the characteristic net-like appearance of reticulocytes under a microscope.

There are several possible causes of reticulocytosis, including:

1. Inherited disorders such as hereditary elliptocytosis, hereditary spherocytosis, and pyruvate kinase (PK) deficiency.
2. Acquired disorders such as hemolytic anemia, thalassemia, and sickle cell disease.
3. Infections such as malaria, dengue fever, and babesiosis.
4. Medications such as antibiotics, chemotherapy drugs, and anti-inflammatory medications.
5. Other conditions such as chronic kidney disease, liver disease, and autoimmune disorders.

Reticulocytosis can be diagnosed through a blood test called a complete blood count (CBC) or a reticulocyte count. Treatment depends on the underlying cause of the condition. In some cases, no treatment may be necessary, while in other cases, medication or blood transfusions may be required.

The symptoms of RCPA can vary depending on the severity of the condition and may include:

* Severe anemia
* Fatigue
* Pale skin
* Shortness of breath
* Increased risk of bleeding

Diagnosis of RCPA typically involves a combination of physical examination, medical history, and laboratory tests, including blood counts, genetic analysis, and bone marrow aspiration. Treatment for RCPA may involve blood transfusions, iron chelation therapy, and in some cases, hematopoietic stem cell transplantation.

The prognosis for RCPA is generally poor, with a high risk of bleeding and death in early childhood if left untreated. However, with timely diagnosis and appropriate treatment, patients with RCPA can have a good quality of life and a normal lifespan.

Types of Kidney Diseases:

1. Acute Kidney Injury (AKI): A sudden and reversible loss of kidney function that can be caused by a variety of factors, such as injury, infection, or medication.
2. Chronic Kidney Disease (CKD): A gradual and irreversible loss of kidney function that can lead to end-stage renal disease (ESRD).
3. End-Stage Renal Disease (ESRD): A severe and irreversible form of CKD that requires dialysis or a kidney transplant.
4. Glomerulonephritis: An inflammation of the glomeruli, the tiny blood vessels in the kidneys that filter waste products.
5. Interstitial Nephritis: An inflammation of the tissue between the tubules and blood vessels in the kidneys.
6. Kidney Stone Disease: A condition where small, hard mineral deposits form in the kidneys and can cause pain, bleeding, and other complications.
7. Pyelonephritis: An infection of the kidneys that can cause inflammation, damage to the tissues, and scarring.
8. Renal Cell Carcinoma: A type of cancer that originates in the cells of the kidney.
9. Hemolytic Uremic Syndrome (HUS): A condition where the immune system attacks the platelets and red blood cells, leading to anemia, low platelet count, and damage to the kidneys.

Symptoms of Kidney Diseases:

1. Blood in urine or hematuria
2. Proteinuria (excess protein in urine)
3. Reduced kidney function or renal insufficiency
4. Swelling in the legs, ankles, and feet (edema)
5. Fatigue and weakness
6. Nausea and vomiting
7. Abdominal pain
8. Frequent urination or polyuria
9. Increased thirst and drinking (polydipsia)
10. Weight loss

Diagnosis of Kidney Diseases:

1. Physical examination
2. Medical history
3. Urinalysis (test of urine)
4. Blood tests (e.g., creatinine, urea, electrolytes)
5. Imaging studies (e.g., X-rays, CT scans, ultrasound)
6. Kidney biopsy
7. Other specialized tests (e.g., 24-hour urinary protein collection, kidney function tests)

Treatment of Kidney Diseases:

1. Medications (e.g., diuretics, blood pressure medication, antibiotics)
2. Diet and lifestyle changes (e.g., low salt intake, increased water intake, physical activity)
3. Dialysis (filtering waste products from the blood when the kidneys are not functioning properly)
4. Kidney transplantation ( replacing a diseased kidney with a healthy one)
5. Other specialized treatments (e.g., plasmapheresis, hemodialysis)

Prevention of Kidney Diseases:

1. Maintaining a healthy diet and lifestyle
2. Monitoring blood pressure and blood sugar levels
3. Avoiding harmful substances (e.g., tobacco, excessive alcohol consumption)
4. Managing underlying medical conditions (e.g., diabetes, high blood pressure)
5. Getting regular check-ups and screenings

Early detection and treatment of kidney diseases can help prevent or slow the progression of the disease, reducing the risk of complications and improving quality of life. It is important to be aware of the signs and symptoms of kidney diseases and seek medical attention if they are present.

CPE can cause a range of symptoms, including:

* Abnormal movements or automatisms (e.g., chewing, grasping, or repetitive gestures)
* Confusion, disorientation, or loss of awareness
* Abnormal sensations (e.g., numbness, tingling, or burning)
* Vision changes (e.g., blurring, double vision, or loss of peripheral vision)
* Difficulty speaking or understanding speech
* Memory impairment or confusion

In contrast to simple partial seizures, which may be brief and non-disruptive, CPE can last longer (up to several minutes) and may cause more significant disruption to daily activities. In addition, people with CPE may experience postictal (post-seizure) symptoms such as confusion, fatigue, or irritability that can last for hours or even days after the seizure ends.

CPE is often difficult to diagnose, as the symptoms can be subtle and may not always be immediately recognizable as a seizure. In addition, people with CPE may experience a variety of other conditions, such as depression, anxiety, or cognitive impairment, which can make it even more challenging to diagnose and manage their epilepsy effectively.

The exact cause of CPE is not always known, but it is believed to be related to abnormal electrical activity in specific areas of the brain. In some cases, CPE may be triggered by certain activities or stimuli (e.g., stress, alcohol, or sleep deprivation), although this is not always the case.

Treatment for CPE typically involves anticonvulsant medications, which can help to reduce or eliminate seizures. In some cases, surgery may be recommended to remove the affected area of the brain that is causing the seizures. Other therapies, such as cognitive-behavioral therapy (CBT) or relaxation techniques, may also be helpful in managing the symptoms of CPE and improving quality of life for people with this condition.

Overall, CPE can have a significant impact on daily life, but with proper diagnosis and treatment, it is possible to manage the condition and improve outcomes for individuals affected by it.

The diagnosis of GVHD is based on a combination of clinical findings, laboratory tests, and biopsies. Treatment options include immunosuppressive drugs, corticosteroids, and in severe cases, stem cell transplantation reversal or donor lymphocyte infusion.

Prevention of GVHD includes selecting the right donor, using conditioning regimens that minimize damage to the recipient's bone marrow, and providing appropriate immunosuppression after transplantation. Early detection and management of GVHD are critical to prevent long-term complications and improve survival rates.

There are several types of lymphoma, including:

1. Hodgkin lymphoma: This is a type of lymphoma that originates in the white blood cells called Reed-Sternberg cells. It is characterized by the presence of giant cells with multiple nucleoli.
2. Non-Hodgkin lymphoma (NHL): This is a type of lymphoma that does not meet the criteria for Hodgkin lymphoma. There are many subtypes of NHL, each with its own unique characteristics and behaviors.
3. Cutaneous lymphoma: This type of lymphoma affects the skin and can take several forms, including cutaneous B-cell lymphoma and cutaneous T-cell lymphoma.
4. Primary central nervous system (CNS) lymphoma: This is a rare type of lymphoma that develops in the brain or spinal cord.
5. Post-transplantation lymphoproliferative disorder (PTLD): This is a type of lymphoma that develops in people who have undergone an organ transplant, often as a result of immunosuppressive therapy.

The symptoms of lymphoma can vary depending on the type and location of the cancer. Some common symptoms include:

* Swollen lymph nodes
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching

Lymphoma is diagnosed through a combination of physical examination, imaging tests (such as CT scans or PET scans), and biopsies. Treatment options for lymphoma depend on the type and stage of the cancer, and may include chemotherapy, radiation therapy, immunotherapy, or stem cell transplantation.

Overall, lymphoma is a complex and diverse group of cancers that can affect people of all ages and backgrounds. While it can be challenging to diagnose and treat, advances in medical technology and research have improved the outlook for many patients with lymphoma.

There are several types of tachycardia, including:

1. Sinus tachycardia: This is the most common type and is caused by an increase in the rate of the normal sinus node. It is often seen in response to physical activity or stress.
2. Atrial fibrillation: This is a type of arrhythmia where the heart's upper chambers (atria) contract irregularly and rapidly, leading to a rapid heart rate.
3. Ventricular tachycardia: This is a type of arrhythmia where the heart's lower chambers (ventricles) contract rapidly, often with a rate above 100 bpm.
4. Premature ventricular contractions (PVCs): These are early or extra beats that originate in the ventricles, causing a rapid heart rate.

Tachycardia can cause a range of symptoms, including palpitations, shortness of breath, chest pain, and dizziness. In severe cases, it can lead to cardiac arrhythmias, heart failure, and even death.

Diagnosis of tachycardia typically involves a physical examination, electrocardiogram (ECG), and other tests such as stress tests or echocardiography. Treatment options vary depending on the underlying cause, but may include medications to regulate the heart rate, cardioversion to restore a normal heart rhythm, or in severe cases, implantation of a pacemaker or defibrillator.

Sickle cell trait is relatively common in certain populations, such as people of African, Mediterranean, or Middle Eastern descent. It is estimated that about 1 in 12 African Americans carry the sickle cell gene, and 1 in 500 are homozygous for the trait (meaning they have two copies of the sickle cell gene).

Although people with sickle cell trait do not develop sickle cell anemia, they can experience certain complications related to the trait. For example, they may experience episodes of hemolytic crisis, which is a condition in which red blood cells are destroyed faster than they can be replaced. This can occur under certain conditions, such as dehydration or infection.

There are several ways that sickle cell trait can affect an individual's life. For example, some people with the trait may experience discrimination or stigma based on their genetic status. Additionally, individuals with sickle cell trait may be more likely to experience certain health problems, such as kidney disease or eye damage, although these risks are generally low.

There is no cure for sickle cell trait, but it can be managed through proper medical care and self-care. Individuals with the trait should work closely with their healthcare provider to monitor their health and address any complications that arise.

Overall, sickle cell trait is a relatively common genetic condition that can have significant implications for an individual's life. It is important for individuals with the trait to understand their risk factors and take steps to manage their health and well-being.

In the medical field, fatigue is often evaluated using a combination of physical examination, medical history, and laboratory tests to determine its underlying cause. Treatment for fatigue depends on the underlying cause, but may include rest, exercise, stress management techniques, and medication.

Some common causes of fatigue in the medical field include:

1. Sleep disorders, such as insomnia or sleep apnea
2. Chronic illnesses, such as diabetes, heart disease, or arthritis
3. Infections, such as the flu or a urinary tract infection
4. Medication side effects
5. Poor nutrition or hydration
6. Substance abuse
7. Chronic stress
8. Depression or anxiety
9. Hormonal imbalances
10. Autoimmune disorders, such as thyroiditis or lupus.

Fatigue can also be a symptom of other medical conditions, such as:

1. Anemia
2. Hypoglycemia (low blood sugar)
3. Hypothyroidism (underactive thyroid)
4. Hyperthyroidism (overactive thyroid)
5. Chronic fatigue syndrome
6. Fibromyalgia
7. Vasculitis
8. Cancer
9. Heart failure
10. Liver or kidney disease.

It is important to seek medical attention if fatigue is severe, persistent, or accompanied by other symptoms such as fever, pain, or difficulty breathing. A healthcare professional can diagnose and treat the underlying cause of fatigue, improving overall quality of life.

The prognosis for mantle-cell lymphoma is generally poor, with a five-year survival rate of approximately 40%. Treatment options include chemotherapy, immunotherapy, and autologous stem-cell transplantation. The disease often recurs after initial therapy, and subsequent treatments may be less effective.

Mantle-cell lymphoma can be difficult to distinguish from other types of non-Hodgkin lymphoma, such as follicular lymphoma or diffuse large B-cell lymphoma, and a correct diagnosis is important for determining appropriate treatment.

Slide: Mantle Cell Lymphoma (Image courtesy of Nephron/Wikimedia Commons)

There are two main types of Renal Insufficiency:

1. Acute Kidney Injury (AKI): This is a sudden and reversible decrease in kidney function, often caused by injury, sepsis, or medication toxicity. AKI can resolve with appropriate treatment and supportive care.
2. Chronic Renal Insufficiency (CRI): This is a long-standing and irreversible decline in kidney function, often caused by diabetes, high blood pressure, or chronic kidney disease. CRI can lead to ESRD if left untreated.

Signs and symptoms of Renal Insufficiency may include:

* Decreased urine output
* Swelling in the legs and ankles (edema)
* Fatigue
* Nausea and vomiting
* Shortness of breath (dyspnea)
* Pain in the back, flank, or abdomen

Diagnosis of Renal Insufficiency is typically made through a combination of physical examination, medical history, laboratory tests, and imaging studies. Laboratory tests may include urinalysis, blood urea nitrogen (BUN) and creatinine levels, and a 24-hour urine protein collection. Imaging studies, such as ultrasound or CT scans, may be used to evaluate the kidneys and rule out other possible causes of the patient's symptoms.

Treatment of Renal Insufficiency depends on the underlying cause and the severity of the condition. Treatment may include medications to control blood pressure, manage fluid balance, and reduce proteinuria (excess protein in the urine). In some cases, dialysis or a kidney transplant may be necessary.

Prevention of Renal Insufficiency includes managing underlying conditions such as diabetes and hypertension, avoiding nephrotoxic medications and substances, and maintaining a healthy diet and lifestyle. Early detection and treatment of acute kidney injury can also help prevent the development of chronic renal insufficiency.

In conclusion, Renal Insufficiency is a common condition that can have significant consequences if left untreated. It is important for healthcare providers to be aware of the causes, symptoms, and diagnosis of Renal Insufficiency, as well as the treatment and prevention strategies available. With appropriate management, many patients with Renal Insufficiency can recover and maintain their kidney function over time.

Pre-B ALL is characterized by the abnormal growth of immature white blood cells called B lymphocytes. These cells are produced in the bone marrow and are normally present in the blood. In Pre-B ALL, the abnormal B cells accumulate in the bone marrow, blood, and other organs, crowding out normal cells and causing a variety of symptoms.

The symptoms of Pre-B ALL can vary depending on the individual patient, but may include:

* Fatigue
* Easy bruising or bleeding
* Frequent infections
* Swollen lymph nodes
* Enlarged liver or spleen
* Bone pain
* Headaches
* Confusion or seizures (in severe cases)

Pre-B ALL is most commonly diagnosed in children, but it can also occur in adults. Treatment typically involves a combination of chemotherapy and sometimes bone marrow transplantation. The prognosis for Pre-B ALL is generally good, especially in children, with a high survival rate if treated promptly and effectively. However, the cancer can be more difficult to treat in adults, and the prognosis may be less favorable.

Overall, Pre-B ALL is a rare and aggressive form of leukemia that requires prompt and specialized treatment to improve outcomes for patients.

This definition of 'Epilepsy, Generalized' is from the Health Dictionary - a medical glossary for the layman.

Please note that this definition is an approximation and is not intended to be taken as a formal definition.

Vomiting can be caused by a variety of factors, such as:

1. Infection: Viral or bacterial infections can inflame the stomach and intestines, leading to vomiting.
2. Food poisoning: Consuming contaminated or spoiled food can cause vomiting.
3. Motion sickness: Traveling by car, boat, plane, or other modes of transportation can cause motion sickness, which leads to vomiting.
4. Alcohol or drug overconsumption: Drinking too much alcohol or taking certain medications can irritate the stomach and cause vomiting.
5. Pregnancy: Hormonal changes during pregnancy can cause nausea and vomiting, especially during the first trimester.
6. Other conditions: Vomiting can also be a symptom of other medical conditions such as appendicitis, pancreatitis, and migraines.

When someone is vomiting, they may experience:

1. Nausea: A feeling of queasiness or sickness in the stomach.
2. Abdominal pain: Crampy or sharp pain in the abdomen.
3. Diarrhea: Loose, watery stools.
4. Dehydration: Loss of fluids and electrolytes.
5. Headache: A throbbing headache can occur due to dehydration.
6. Fatigue: Weakness and exhaustion.

Treatment for vomiting depends on the underlying cause, but may include:

1. Fluid replacement: Drinking fluids to replenish lost electrolytes and prevent dehydration.
2. Medications: Anti-inflammatory drugs or antibiotics may be prescribed to treat infections or other conditions causing vomiting.
3. Rest: Resting the body and avoiding strenuous activities.
4. Dietary changes: Avoiding certain foods or substances that trigger vomiting.
5. Hospitalization: In severe cases of vomiting, hospitalization may be necessary to monitor and treat underlying conditions.

It is important to seek medical attention if the following symptoms occur with vomiting:

1. Severe abdominal pain.
2. Fever above 101.5°F (38.6°C).
3. Blood in vomit or stools.
4. Signs of dehydration, such as excessive thirst, dark urine, or dizziness.
5. Vomiting that lasts for more than 2 days.
6. Frequent vomiting with no relief.

Symptoms of Pouchitis:

* Diarrhea
* Abdominal pain
* Fever
* Nausea and vomiting
* Blood in stool

Treatment of Pouchitis:

* Antibiotics to treat any underlying infections
* Increased fluid and electrolyte intake to prevent dehydration
* Use of anti-inflammatory medications such as mesalamine or corticosteroids to reduce inflammation
* In severe cases, surgical intervention may be necessary to remove the pouch and replace it with a colostomy bag.

Prevention of Pouchitis:

* Proper care and maintenance of the pouch, including regular cleaning and drying
* Avoiding use of harsh soaps or chemicals near the pouch
* Avoiding insertion of any foreign objects into the pouch
* Following a balanced diet and avoiding spicy or fatty foods that can irritate the pouch.

PMF is a chronic disease that worsens over time, and it can lead to complications such as bleeding, infection, and bone damage. Treatment options include medications to reduce symptoms and slow the progression of the disease, as well as blood transfusions and splenectomy (removal of the spleen) in severe cases. The median age at diagnosis is around 60 years old, and the disease affects approximately 2-5 cases per million people per year.

Sources:

* American Cancer Society. (2019). What is primary myelofibrosis? Retrieved from
* Leukemia and Lymphoma Society. (n.d.). Primary Myelofibrosis. Retrieved from

The condition is caused by sensitization of the mother's immune system to the Rh factor, which can occur when the mother's blood comes into contact with the fetus's blood during pregnancy or childbirth. The antibodies produced by the mother's immune system can attack the red blood cells of the fetus, leading to hemolytic anemia and potentially causing stillbirth or death in the newborn.

Erythroblastosis fetalis is diagnosed through blood tests that measure the levels of antibodies against the Rh factor. Treatment typically involves the administration of Rh immune globulin, which can help to prevent the mother's immune system from producing more antibodies against the Rh factor and reduce the risk of complications for the fetus. In severe cases, a blood transfusion may be necessary to increase the newborn's red blood cell count.

Erythroblastosis fetalis is a serious condition that requires close monitoring and proper medical management to prevent complications and ensure the best possible outcome for both the mother and the baby.

There are several subtypes of lymphoma, B-cell, including:

1. Diffuse large B-cell lymphoma (DLBCL): This is the most common type of B-cell lymphoma and typically affects older adults.
2. Follicular lymphoma: This type of lymphoma grows slowly and often does not require treatment for several years.
3. Marginal zone lymphoma: This type of lymphoma develops in the marginal zone of the spleen or other lymphoid tissues.
4. Hodgkin lymphoma: This is a type of B-cell lymphoma that is characterized by the presence of Reed-Sternberg cells, which are abnormal cells that can be identified under a microscope.

The symptoms of lymphoma, B-cell can vary depending on the subtype and the location of the tumor. Common symptoms include swollen lymph nodes, fatigue, fever, night sweats, and weight loss.

Treatment for lymphoma, B-cell usually involves chemotherapy, which is a type of cancer treatment that uses drugs to kill cancer cells. Radiation therapy may also be used in some cases. In some cases, bone marrow or stem cell transplantation may be recommended.

Prognosis for lymphoma, B-cell depends on the subtype and the stage of the disease at the time of diagnosis. In general, the prognosis is good for patients with early-stage disease, but the cancer can be more difficult to treat if it has spread to other parts of the body.

Prevention of lymphoma, B-cell is not possible, as the exact cause of the disease is not known. However, avoiding exposure to certain risk factors, such as viral infections and pesticides, may help reduce the risk of developing the disease. Early detection and treatment can also improve outcomes for patients with lymphoma, B-cell.

Lymphoma, B-cell is a type of cancer that affects the immune system and can be treated with chemotherapy and other therapies. The prognosis varies depending on the subtype and stage of the disease at diagnosis. Prevention is not possible, but early detection and treatment can improve outcomes for patients with this condition.

Examples of autoimmune diseases include:

1. Rheumatoid arthritis (RA): A condition where the immune system attacks the joints, leading to inflammation, pain, and joint damage.
2. Lupus: A condition where the immune system attacks various body parts, including the skin, joints, and organs.
3. Hashimoto's thyroiditis: A condition where the immune system attacks the thyroid gland, leading to hypothyroidism.
4. Multiple sclerosis (MS): A condition where the immune system attacks the protective covering of nerve fibers in the central nervous system, leading to communication problems between the brain and the rest of the body.
5. Type 1 diabetes: A condition where the immune system attacks the insulin-producing cells in the pancreas, leading to high blood sugar levels.
6. Guillain-Barré syndrome: A condition where the immune system attacks the nerves, leading to muscle weakness and paralysis.
7. Psoriasis: A condition where the immune system attacks the skin, leading to red, scaly patches.
8. Crohn's disease and ulcerative colitis: Conditions where the immune system attacks the digestive tract, leading to inflammation and damage to the gut.
9. Sjögren's syndrome: A condition where the immune system attacks the glands that produce tears and saliva, leading to dry eyes and mouth.
10. Vasculitis: A condition where the immune system attacks the blood vessels, leading to inflammation and damage to the blood vessels.

The symptoms of autoimmune diseases vary depending on the specific disease and the organs or tissues affected. Common symptoms include fatigue, fever, joint pain, skin rashes, and swollen lymph nodes. Treatment for autoimmune diseases typically involves medication to suppress the immune system and reduce inflammation, as well as lifestyle changes such as dietary changes and stress management techniques.

This condition can be caused by various factors such as genetic mutations, infections, autoimmune disorders, and certain medications. In severe cases, agranulocytosis can lead to life-threatening infections that require prompt medical treatment.

Some of the common symptoms of agranulocytosis include fever, chills, sore throat, fatigue, and recurring infections. Diagnosis is typically made through blood tests that measure the number and function of white blood cells, including granulocytes. Treatment options for agranulocytosis depend on the underlying cause, but may include antibiotics, antiviral medications, and immunoglobulin replacement therapy in severe cases.

Types of Infection:

1. Bacterial Infections: These are caused by the presence of harmful bacteria in the body. Examples include pneumonia, urinary tract infections, and skin infections.
2. Viral Infections: These are caused by the presence of harmful viruses in the body. Examples include the common cold, flu, and HIV/AIDS.
3. Fungal Infections: These are caused by the presence of fungi in the body. Examples include athlete's foot, ringworm, and candidiasis.
4. Parasitic Infections: These are caused by the presence of parasites in the body. Examples include malaria, giardiasis, and toxoplasmosis.

Symptoms of Infection:

1. Fever
2. Fatigue
3. Headache
4. Muscle aches
5. Skin rashes or lesions
6. Swollen lymph nodes
7. Sore throat
8. Coughing
9. Diarrhea
10. Vomiting

Treatment of Infection:

1. Antibiotics: These are used to treat bacterial infections and work by killing or stopping the growth of bacteria.
2. Antiviral medications: These are used to treat viral infections and work by interfering with the replication of viruses.
3. Fungicides: These are used to treat fungal infections and work by killing or stopping the growth of fungi.
4. Anti-parasitic medications: These are used to treat parasitic infections and work by killing or stopping the growth of parasites.
5. Supportive care: This includes fluids, nutritional supplements, and pain management to help the body recover from the infection.

Prevention of Infection:

1. Hand washing: Regular hand washing is one of the most effective ways to prevent the spread of infection.
2. Vaccination: Getting vaccinated against specific infections can help prevent them.
3. Safe sex practices: Using condoms and other safe sex practices can help prevent the spread of sexually transmitted infections.
4. Food safety: Properly storing and preparing food can help prevent the spread of foodborne illnesses.
5. Infection control measures: Healthcare providers use infection control measures such as wearing gloves, masks, and gowns to prevent the spread of infections in healthcare settings.

Some common types of sclerosis include:

1. Multiple sclerosis (MS): This is an autoimmune disease that affects the central nervous system (CNS), causing inflammation and damage to the protective covering of nerve fibers, leading to communication problems between the brain and the rest of the body.
2. Systemic sclerosis (SSc): Also known as scleroderma, this is a chronic autoimmune disease that affects the skin and internal organs, causing hardening and tightening of the skin and scar tissue formation in the affected areas.
3. Progressive supranuclear palsy (PSP): This is a rare brain disorder that affects movement, balance, and eye movements, caused by degeneration of certain cells in the brainstem.
4. Primary lateral sclerosis (PLS): This is a rare neurodegenerative disorder that affects the motor neurons in the spinal cord, leading to weakness in the muscles of the legs, feet, and hands.
5. Tuberous sclerosis complex (TSC): This is a rare genetic disorder that causes non-cancerous tumors to grow in organs such as the brain, heart, kidneys, and lungs.

Symptoms of sclerosis vary depending on the type and location of the condition. Common symptoms include muscle weakness or stiffness, difficulty with movement and coordination, numbness or tingling sensations, and changes in sensation or perception. Treatment options for sclerosis depend on the specific type and severity of the condition, and may include medications, physical therapy, and lifestyle modifications.

Hydrothorax is a condition where there is an accumulation of fluid in the pleural space, which is the area between the lungs and the chest wall. This condition can occur due to various causes such as heart failure, pulmonary embolism, or cancer. The excess fluid in the pleural space can put pressure on the lungs and make it difficult for them to expand and function properly.

Symptoms of hydrothorax may include:

1. Shortness of breath
2. Chest pain
3. Coughing up pink, frothy liquid
4. Fatigue
5. Swelling in the legs, ankles, or feet

Hydrothorax can be diagnosed through various tests such as chest X-rays, CT scans, and ultrasound. Treatment options for hydrothorax depend on the underlying cause of the condition. In some cases, draining the excess fluid from the pleural space may be necessary to relieve symptoms and improve lung function. Medications such as diuretics or oxygen therapy may also be prescribed to help manage symptoms.

There are many different types of seizures, each with its own unique set of symptoms. Some common types of seizures include:

1. Generalized seizures: These seizures affect both sides of the brain and can cause a range of symptoms, including convulsions, loss of consciousness, and muscle stiffness.
2. Focal seizures: These seizures affect only one part of the brain and can cause more specific symptoms, such as weakness or numbness in a limb, or changes in sensation or vision.
3. Tonic-clonic seizures: These seizures are also known as grand mal seizures and can cause convulsions, loss of consciousness, and muscle stiffness.
4. Absence seizures: These seizures are also known as petit mal seizures and can cause a brief loss of consciousness or staring spell.
5. Myoclonic seizures: These seizures can cause sudden, brief muscle jerks or twitches.
6. Atonic seizures: These seizures can cause a sudden loss of muscle tone, which can lead to falls or drops.
7. Lennox-Gastaut syndrome: This is a rare and severe form of epilepsy that can cause multiple types of seizures, including tonic, atonic, and myoclonic seizures.

Seizures can be diagnosed through a combination of medical history, physical examination, and diagnostic tests such as electroencephalography (EEG) or imaging studies. Treatment for seizures usually involves anticonvulsant medications, but in some cases, surgery or other interventions may be necessary.

Overall, seizures are a complex and multifaceted symptom that can have a significant impact on an individual's quality of life. It is important to seek medical attention if you or someone you know is experiencing seizures, as early diagnosis and treatment can help to improve outcomes and reduce the risk of complications.

There are several different types of preleukemia, including:

1. Myelodysplastic syndrome (MDS): A condition where there is a defect in the development of immature blood cells in the bone marrow, leading to an overproduction of blasts and a decrease in the number of healthy red blood cells, white blood cells, and platelets.
2. Myeloproliferative neoplasms (MPNs): A group of conditions characterized by an overproduction of one or more types of blood cells, including red blood cells, white blood cells, and platelets. MPNs can progress to leukemia over time.
3. Chronic myelogenous leukemia (CML): A type of leukemia that develops from a preleukemic condition called chronic myeloid leukemia. CML is characterized by the presence of a genetic abnormality known as the Philadelphia chromosome, which leads to an overproduction of white blood cells.
4. Acute myeloid leukemia (AML): A type of leukemia that can develop from preleukemic conditions such as MDS and MPNs. AML is characterized by the rapid growth of immature white blood cells in the bone marrow, which can crowd out healthy cells and lead to a decrease in the number of normal red blood cells, white blood cells, and platelets.

Preleukemia can be difficult to diagnose, as it often does not have clear symptoms in its early stages. However, doctors may use a variety of tests, including blood tests and bone marrow biopsies, to detect abnormalities in the blood or bone marrow that could indicate preleukemia.

Treatment for preleukemia depends on the specific type of condition and its severity. Some common treatments include:

1. Chemotherapy: A type of cancer treatment that uses drugs to kill cancer cells. Chemotherapy may be used to treat preleukemia, particularly in cases where there are abnormalities in the blood or bone marrow.
2. Blood transfusions: Transfusions of healthy red blood cells, platelets, or plasma may be given to patients with preleukemia who have low levels of these cells.
3. Supportive care: Patients with preleukemia may require supportive care, such as antibiotics or other medications, to manage symptoms and prevent complications.
4. Stem cell transplantation: In some cases, stem cell transplantation may be recommended for patients with preleukemia who have a high risk of developing acute leukemia. This involves replacing the patient's defective bone marrow stem cells with healthy ones from a donor.

Overall, early detection and treatment of preleukemia can improve outcomes and reduce the risk of developing acute leukemia. If you have been diagnosed with preleukemia or are experiencing symptoms that may indicate preleukemia, it is important to discuss your treatment options with your healthcare provider.

... is a type of myelodysplastic syndrome. RARS is characterized by 5% or less myeloblasts ... "Pathology of Refractory Anemia With Ring Sideroblasts". Retrieved 28 August 2013. v t e (Articles with short description, Short ... RARS is distinguished from refractory anemia by having 15% or more ringed sideroblasts among the erythroid precursors in the ...
... refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) ... Refractory anemia with excess of blasts (RAEB) is a type of myelodysplastic syndrome with a marrow blast percentage of 5% to 19 ... July 2006). "An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid ...
"Severe Anemia". Hart GB, Lennon PA, Strauss MB (1987). "Hyperbaric oxygen in exceptional acute blood-loss anemia". J. ... "Refractory Osteomyelitis". Retrieved 2011-08-21. Mader JT, Adams KR, Sutton TE (1987). "Infectious diseases: pathophysiology ... refractory); Delayed radiation injury (soft tissue and bony necrosis); Skin grafts and flaps (compromised); Thermal burns. ... anemia); Idiopathic sudden sensorineural hearing loss; Intracranial abscess; Mucormycosis, especially rhinocerebral disease in ...
Hyperanemia is a severe form of anemia, in which the hematocrit is below 10%. Refractory anemia, an anemia which does not ... Look up anemia in Wiktionary, the free dictionary. Anemia, U.S. National Library of Medicine [About Anemia] (CS1: long volume ... Fanconi anemia is a hereditary disorder or defect featuring aplastic anemia and various other abnormalities. Anemia of kidney ... Anemia of folate deficiency, as with vitamin B12, causes megaloblastic anemia Anemia of prematurity, by diminished ...
Refractory idiopathic thrombocytopenic purpura. Hemolytic anemias. Cytopenias. Thromboembolic disorders and cancer-related ... refractory Multiple myeloma and Lymphoma Microangiopathic hemolytic anemias Consultation Services for Hemoglobinpathy. ... Refractory idiopathic thrombocytopenic purpura and other platelets disorder (eg Glanzman's thrombathenia). Pediatric Hematology ... aplastic anemia, myelodysplastic syndromes and hereditary bone marrow failure syndromes. High dose chemotherapy and stem cells ...
GLRX5 Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive; 205950; SLC25A38 Anemia, sideroblastic, with ataxia; ... RHAG Anemia, hypochromic microcytic; 206100; NRAMP2 Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive; 205950; ... SCN5A Heinz body anemia; 140700; HBA2 Heinz body anemias, alpha-; 140700; HBA1 Heinz body anemias, beta-; 140700; HBB HELLP ... RPL5 Diamond-Blackfan anemia 7; 612562; RPL11 Diamond-Blackfan anemia 8; 612563; RPS7 Diamond-Blackfan anemia 9; 613308; RPS10 ...
Before then, RCC cases were classified as childhood aplastic anemia. RCC is the most common form of MDS in children and ... Refractory cytopenia of childhood is a subgroup of myelodysplastic syndrome (MDS), having been added to the World Health ... "Classification of childhood aplastic anemia and myelodysplastic syndrome". Hematology. 2011: 84-9. doi:10.1182/asheducation- ...
It also occurs in patients with hereditary iron refractory iron-deficiency anemia (IRIDA). Patients with IRIDA have very low ... Hypochromic anemia is also caused by thalassemia and congenital disorders like Benjamin anemia. Microcytic anemia Iron ... Hypochromic anemia is a generic term for any type of anemia in which the red blood cells are paler than normal. (Hypo- refers ... Hershko, Chaim; Camaschella, Clara (2014-01-16). "How I treat unexplained refractory iron deficiency anemia". Blood. 123 (3): ...
Mutations in this gene are associated with autosomal recessive pyridoxine-refractory sideroblastic anemia. The GLRX5 gene ... as well as pyridoxine-refractory, autosomal recessive anemia (PRARSA). Cells with mutations in GLRX5 activity show deficiency ... Mutations in the GLRX5 gene have been associated with sideroblastic anemia, variant glycine encephalopathy (also known as non- ... Camaschella C (Oct 2008). "Recent advances in the understanding of inherited sideroblastic anaemia". British Journal of ...
15 May 2003). "Rituximab for the treatment of refractory autoimmune hemolytic anemia in children". Blood. 101 (10): 3857-61. ... Autoimmune hemolytic anemia is a condition in which the red blood cells that normally carry oxygen are destroyed by an ... Liu H, Shao Z, Jing L (2001). "[The effectiveness of cyclosporin A in the treatment of autoimmune hemolytic anemia and Evans ... The off-label use of rituximab (trade name Rituxan) has produced some good results in acute and refractory cases, although ...
May 2003). "Rituximab for the treatment of refractory autoimmune hemolytic anemia in children". Blood. 101 (10): 3857-61. doi: ... Hemolytic anemia is the hemolytic state in which anemia is present, and bone marrow function is inferentially unable to ... AIHA can be classified as warm autoimmune hemolytic anemia or cold autoimmune hemolytic anemia, which includes cold agglutinin ... Although MeSH uses the term "autoimmune hemolytic anemia", some sources prefer the term "immunohemolytic anemia" so drug ...
The treatment for anemia is rest and a diet consisting of high iron foods. Medication can also be used such as:[citation needed ... Refractory cytopenia - caused by bone marrow not producing healthy blood cells, and can be a result of cancer. The symptoms of ... Anemia - a reduction of the red blood cells in the body. Leukopenia - a deficiency of white blood cells, or leukocytes ... The symptoms of anemia include:[citation needed] Fatigue Weakness Shortness of breath Poor concentration Dizziness or feeling ...
... an anticonvulsant used in refractory epilepsy; use is associated with an increased risk of aplastic anemia and liver failure; ... Unacceptably high risk of irreversible, fatal aplastic anemia and gray baby syndrome causes intravenous chloramphenicol to be a ... therapeutic drug monitoring and time to response in treatment-refractory schizophrenia". Clinical Pharmacokinetics. 42 (7): 607 ...
... mutations are found in 60%-80% of patients with refractory anemia with ring sideroblasts (RARS; which is a ...
"A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction ... The syndrome also leads to anemia, low platelet count, and aplastic anemia. It may be confused with transient ... To diagnose Pearson Syndrome a physician can either collect a bone marrow biopsy and look for sideroblastic anemia, a symptom ... Pearson marrow pancreas syndrome (PMPS) is a condition that presents itself with severe reticulocyto-penic anemia. With the ...
"A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients" at ClinicalTrials.gov ... "Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of ... In 2017, the NIH made Eltrombopag a standard of care in aplastic anemia. It has been shown to produce a trilineage ... and severe aplastic anemia. Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis. It is ...
If ineffective, splenectomy should be considered.[citation needed] If refractory to both these therapies, other options include ... Warm antibody autoimmune hemolytic anemia (WAIHA) is the most common form of autoimmune haemolytic anemia. About half of the ... ISBN 0-7216-0187-1. AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) Archived 2009-10-07 at the Wayback Machine By J.L. Jenkins. The Regional ... Case report of warm-antibody autoimmune hemolytic anemia with typical laboratory findings. Clinical Cases and Images The wAIHA ...
Three forms exist and include refractory anemia with ringed sideroblasts (RARS), refractory anemia with ringed sideroblasts and ... Sideroblastic anemia, or sideroachrestic anemia, is a form of anemia in which the bone marrow produces ringed sideroblasts ... Congenital sideroblastic anemia X-linked sideroblastic anemia: This is the most common congenital cause of sideroblastic anemia ... congenital sideroblastic anemia, acquired clonal sideroblastic anemia, and acquired reversible sideroblastic anemia. All cases ...
... inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia - Full Text View - ...
... an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drug's usage to severe refractory ... Two rare but very serious effects include aplastic anemia and serious liver damage. The risk of aplastic anemia is between 1: ... It was urgently withdrawn after 10 cases of aplastic anemia. A "Dear Doctor" letter was sent to 240,000 physicians. September ...
... can be aberrantly expressed in refractory anaemia with excess blasts (RAEB) and may confer a worse prognosis. Also, a lack ...
"Severe refractory autoimmune hemolytic anemia with both warm and cold autoantibodies that responded completely to a single ... Mixed autoimmune hemolytic anemia (MAIHA) is a type of autoimmune hemolytic anemia which combines the features of cold ... "Orphanet: Autoimmune hemolytic anemia, warm type". Orphanet. 2019-02-14. Retrieved 2019-02-15. Das, SudiptaSekhar; Chakrabarty ... Berentsen, Sigbjørn; Sundic, Tatjana (2015-01-29). "Red Blood Cell Destruction in Autoimmune Hemolytic Anemia: Role of ...
"Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia ... Hereditary hemolytic anemias, Disorders of globin and globulin proteins). ... with β-thalassemia trait should be warned that their condition can be misdiagnosed for the common Iron deficiency anemia. They ...
The refractory anemia also called corticosteroid sensitive anemia, is likely due to fibrotic scarring or sclerosis, which is ... Anemia is a consistent feature of Ghosal hematodiaphyseal dysplasia with the severity of said anemia to include multiple blood ... characterized by diaphyseal dysplasia and metaphyseal dysplasia of the long bones and refractory anemia. It is associated with ... After steroid therapy, anemia and most hematological abnormalities resolved themselves after a couple of weeks. This disease ...
... may be caused by vitamin deficiency or chemotherapy, or it may be a sign of refractory anemia, which is a ...
These conditions were lumped together with other diseases under the term "refractory anemia". The first description of " ... The terms refractory neutropenia and refractory thrombocytopenia have sometimes been used to describe these cases. A diagnosis ... ringed sideroblasts when counted among red cell precursors for refractory anemia with ring sideroblasts) Megakaryocytic series ... and a family history may indicate a hereditary form of sideroblastic anemia or Fanconi anemia. MDS most often develops without ...
LSD may easily be missed for other conditions causing anemia, thrombocytopenia, and hepatosplenomegaly, but should be ... considered especially if the patient's disease course has been refractory to antibiotics. The disease is often rapidly fatal, ... pneumothorax Hematologic manifestations such as significant anemia, neutropenia, and thrombocytopenia Constitutional symptoms ...
It is primarily effective in treating absence seizures, but can also be used in refractory temporal lobe epilepsy. It is ... Severe adverse reactions are possible, including Steven Johnson syndrome, nephrotoxicity, hepatitis, aplastic anemia, ...
If the individual doesn't respond to steps 1-3 then they are considered to have refractory symptoms. At this point, anti- ... Sulfasalazine is a good option for people with anemia who cannot take dapsone. Hydroxychloroquine is an antimalarial agent that ... Other options for refractory symptoms of chronic hives include anti-inflammatory medications, omalizumab, and ... It is helpful in therapy-refractory cases and is contraindicated in people with G6PD deficiency. Sulfasalazine, a 5-ASA ...
... and an anemia which in many patients is profound, refractory to traditional therapies (e.g. iron supplements, Erythropoietin), ... They present with anemia, increases in blood eosinophils and monocytes, splenomegaly, and, less often, lymphadenopathy. Bone ... They commonly present with anemia, eosinophilia, monocytosis, and splenomegaly and have their disease classified as chronic ...
the treatment of adults with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell ... of people taking pembrolizumab have included anemia, decreased appetite, headache, dizziness, distortion of the sense of taste ... "FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL". U.S. Food and Drug Administration (FDA) (Press ... relapsed or refractory solid tumors. "Pembrolizumab (Keytruda) Use During Pregnancy". Drugs.com. 24 September 2019. Archived ...
For example, iron deficiency anemia is thought to cause depressed cell-mediated immunity. Some sources state that deficiencies ... Shah N, Ray JG, Kundu S, Sardana D (2017). "Surgical management of chronic hyperplastic candidiasis refractory to systemic ...
... fatigue due to anemia, weight loss, progressive symptomatic lymphadenopathy or spleen enlargement, and anemia due to bone ... Of these, 11 were performed on previously untreated patients, 14 in patients with relapsed or refractory Waldenström. A ... Anemia occurs in about 80% of patients with Waldenström macroglobulinemia. A low white blood cell count, and low platelet count ... anemia, decreased levels of fibrinogen in the blood (hypofibrinogenemia), swollen lymph nodes, neoplastic plasma cells in bone ...
Previously considered "hormone-refractory prostate cancer" or "androgen-independent prostate cancer", the term CRPC emerged ... as well as fatigue due to anemia, and bone pain. One study found that about a third of diagnosed patients had one or more such ... "Prostate cancer (hormone-refractory) - docetaxel". National Institute for Health and Clinical Excellence. 2010-12-10. Archived ... Clarke NW (2005). "Docetaxel for the Treatment of Hormone Refractory Prostate Cancer" (PDF). Archived from the original (PDF) ...
Anaemia is often a cause of dyspnea. Menstruation, particularly if excessive, can contribute to anaemia and to consequential ... air in relieving breathlessness in patients with refractory dyspnea: a double-blind randomized controlled trial". Lancet. 376 ( ... Anemia that develops gradually usually presents with exertional dyspnea, fatigue, weakness, and tachycardia. It may lead to ... "Anemia Affects Body...And Maybe The Mind". Johns Hopkins medicine. 2006. Retrieved 15 May 2020. Haywood, Alison; Duc, ...
The idea that folic acid deficiency could cause megaloblastic anemia was not new. What was new was the idea that drugs could ... Schaffer LC; Schaffer CB; Caretto J (June 1999). "The use of primidone in the treatment of refractory bipolar disorder". Annals ... Folic acid had been found to alleviate the symptoms of megaloblastic anemia in the 1940s, not long after it was discovered, but ... Megaloblastic anemia is actually a group of related disorders with different causes that share morphological characteristics- ...
In refractory cases, plasma exchange may be used. Thrombolysis (removal of the blood clot with "clot buster" medication) has ... especially in combination with oral contraceptive use Sickle cell anemia Dehydration, primarily in infants and children ...
"Refractory" CLL is a disease that no longer responds favorably to treatment within six months following the last cancer therapy ... Enlargement of the spleen and low red blood cells (anemia) may also occur. It typically worsens gradually over years. Risk ... 2017-12-07). "Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High ... warm autoimmune hemolytic anemia in 10-15% of patients, and bone marrow failure. Chronic lymphocytic leukemia may also develop ...
Recurrent or refractory bleeding may lead to need for surgery, although this has become uncommon as a result of improved ... Laboratory findings include anemia, coagulopathy, and an elevated BUN-to-creatinine ratio. A number of medications increase the ... A person with upper gastrointestinal bleeding may also present with complications of anemia, including chest pain, syncope, ...
In the United States it is also indicated for the treatment of relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with ... Additional common adverse reactions include rash, anemia, epistaxis, serous retinal detachment, extremity pain, dyspepsia, ... "FDA approves pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement". U.S. Food and Drug ... single-arm trial that included 28 participants with relapsed or refractory MLNs with FGFR1 rearrangement. Eligible participants ...
ISBN 978-3-642-22696-0. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D (2002). "Impact of tumor hypoxia and anemia on radiation ... and they were approved for the treatment of refractory non-Hodgkin's lymphoma. Intraoperative radiation therapy (IORT) is ...
Chronic pain in patients with ADPKD is often refractory to conservative, noninvasive treatments, but nonopioid analgesics and ... Hypertension Associated liver cysts Uremia due to kidney failure Anemia due to chronic kidney disease Increase RBC or ... April 2017). "Novel treatment protocol for ameliorating refractory, chronic pain in patients with autosomal dominant polycystic ...
Failure to thrive and anaemia may also be present. Lower gastrointestinal bleeding may imply colonic involvement. Muscular EG ( ... acute appendicitis and giant refractory duodenal ulcer. Peripheral blood eosinophilia and elevated serum IgE are usual but not ...
Otsuki T, Furukawa Y, Ikeda K, Endo H, Yamashita T, Shinohara A, Iwamatsu A, Ozawa K, Liu JM (November 2001). "Fanconi anemia ... Furthermore, it explains why lung cancer and other solid tumors are completely refractory to treatments based on these ... "Yeast two-hybrid screens imply involvement of Fanconi anemia proteins in transcription regulation, cell signaling, oxidative ...
"U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic ... The signs and symptoms of ALL are variable and include: Generalized weakness and feeling tired Anemia Dizziness Headache, ... "FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed or Refractory MCL". U.S. Food and Drug ... "FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia". U.S. Food and ...
... a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma". Blood. 119 (9 ... Open-Label Study of Obatoclax Mesylate in Patients with Previously Untreated Myelodysplastic Syndromes with Anemia or ...
While there may be a link between hydroxychloroquine and hemolytic anemia in those with glucose-6-phosphate dehydrogenase ... Steere AC, Angelis SM (October 2006). "Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory ... anemia, bleaching of hair, blisters in mouth and eyes, blood disorders, cardiomyopathy, convulsions, vision difficulties, ... "Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients". Arthritis Care & Research. 70 (3): 481 ...
These would enable a dipole to reach an area that had been refractory and is now able to be depolarised with continuation of ... and death results within six to eight minutes from anemia [ischemia] of the brain and spinal cord". Spontaneous conversion of ... The waves eventually meet and cancel each other out, but, if an area of transient block occurred with a refractory period that ... The length of the refractory period and the time taken for the dipole to travel a certain distance-the propagation velocity- ...
The amplification refractory mutation system (ARMS)". Nucleic Acids Research. 17 (7): 2503-16. doi:10.1093/nar/17.7.2503. PMC ... "Enzymatic Amplification of β-globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia"-the ... "Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia". ...
It is used to fortify foods and treat iron deficiency anemia. Iron(III) sulfate is used in settling minute sewage particles in ... Iron is the sixth most abundant element in the universe, and the most common refractory element. Although a further tiny energy ... "Iron Deficiency Anemia". MediResource. Retrieved 17 December 2008. Milman, N. (1996). "Serum ferritin in Danes: studies of iron ... Most cases of iron-deficiency anemia are mild, but if not treated can cause problems like fast or irregular heartbeat, ...
... as monotherapy is indicated for the treatment of adults with relapsed or refractory hairy cell leukemia ( ... anemia and diarrhea. The prescribing information for moxetumomab pasudotox includes a boxed warning about the risk of ... is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who ... intended for the treatment of relapsed or refractory hairy cell leukemia after two prior systemic therapies including a purine ...
Sandroni P, Davis MD (March 2006). "Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia ... and pernicious anemia. The following table shows the history of the nomenclature of Erythromelalgia: Because of the severity of ...
With the viscosity of a sol adjusted into a proper range, both optical quality glass fiber and refractory ceramic fiber can be ... Changes to viscosity has been shown to be linked with diseases like hyperviscosity, hypertension, sickle cell anemia, and ...
Iron-refractory iron deficiency anemia is one of many types of anemia , which is a group of conditions characterized by a ... medlineplus.gov/genetics/condition/iron-refractory-iron-deficiency-anemia/ Iron-refractory iron deficiency anemia. ... Iron-refractory iron deficiency anemia is one of many types of anemia. , which is a group of conditions characterized by a ... Although iron deficiency anemia is relatively common, the prevalence of the iron-refractory form of the disease is unknown. At ...
Individuals with refractory anemia and clinical suspicion of leukemia. Risk Assessment and management. ...
Treatment of Refractory Diamond-Blackfan Anemia with Eltrombopag. This study is NOT currently recruiting participants. ... Diamond-Blackfan anemia defined as anemia presenting on or before the third year of life with reticulocytopenia and greatly ... Clinically-significant anemia as defined as either: --hemoglobin less than 9.0 g/dL --red cell transfusion of at least 2 units ... Diamond-Blackfan anemia (DBA) is treated with steroids. But some people cannot take steroids, or steroids don t work. Other ...
NEW INSIGHTS INTO THE BIOLOGY OF REFRACTORY ANEMIA WITH RING SIDEROBLASTS (RARS) AND IDENTIFICATION OF ERYTHROID G-CSF TARGETS ... NEW INSIGHTS INTO THE BIOLOGY OF REFRACTORY ANEMIA WITH RING SIDEROBLASTS (RARS) AND IDENTIFICATION OF ERYTHROID G-CSF TARGETS ...
Refractory leukemia or MDS.. *Bone marrow failure syndromes, except for Fanconi Anemia ... Active Comparator: Arm 3 - Refractory Leukemia/Lymphoma Arm 3 - patients with refractory leukemia or lymphoma who have been ... Patients with refractory disease are eligible, unless has bulky disease and an estimated tumor doubling time of less than one ... Chronic myelogenous leukemia (CML) in refractory blast crisis. *Large cell lymphoma, mantle cell lymphoma and Hodgkin disease ...
Refractory Anemia With Excess Blasts * Secondary Polycythemia * Sickle Cell Disease * Small Cell Lung Cancer ...
Anemia is further broadly subcategorized into acute and chronic. ... Anemia is defined as an absolute reduction in the quantity of ... Clinical outcomes of transfusion-associated iron overload in patients with refractory chronic anemia. Patient Prefer Adherence ... Normocytic anemia. Normocytic anemia is further divided into 2 broad categories: anemia with primary bone marrow involvement ... Hemolytic anemia. This type of anemia includes sickle cell anemia, thrombotic thrombocytopenic purpura (TTP), hemolytic uremic ...
On day 10, the lymphocyte level had returned to reference range and the anemia had become regenerative. However, the patients ... On day 5, because of refractory ARDS, venoarterial extracorporal membrane oxygenation was started. On day 6, the results of a ... Hematologic tests showed nonregenerative anemia (hemoglobin concentration 9 g/dL) and leukopenia (2.2 × 109 leukocytes/L) with ...
Refractory Severe Aplastic Anemia The approval was based on data from a single-arm, single-center, open-label trial (Study ... Refractory Severe Aplastic Anemia The approval was based on data from a single-arm, single-center, open-label trial (Study ... Refractory Severe Aplastic Anemia. * Use lowest dose to achieve and maintain a hematologic response. Dose adjustments are based ... Refractory Severe Aplastic Anemia. * Use lowest dose to achieve and maintain a hematologic response. Dose adjustments are based ...
Refractory anemia with sideroblasts. 9983/3. Refractory anemia with excess blasts. 9984/3. Refractory anemia with excess blasts ...
Disturbances of T Lymphocyte Subsets Preceding Refractory Anemia with Excess Blasts in Transformation in a Child Acta Haematol ...
High-dose Romiplostim Accelerates Hematologic Recovery in Patients With Aplastic Anemia Refractory to Eltrombopag Jul 2020 ... aplastic anemia Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal ... aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH) Genetics of Progression From MDS to ... The Aplastic Anemia and MDS International Foundation. (800) 747-2820 , (301) 279-7202. 4330 East West Highway, Suite 230. ...
Li N, Song Y, Zhou J, Fang B. Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia. J Hematol Oncol. ( ... Bone Marrow Fat and Aplastic Anemia. Aplastic anemia (AA) is a complex bone marrow failure syndrome characterized by extremely ... Therapeutic effect of lithium chloride combined with cyclosporine A on mouse model with aplastic anemia]. Zhongguo Shi Yan Xue ... Song Y, Li N, Liu Y, Fang B. Improved outcome of adults with aplastic anaemia treated with arsenic trioxide plus ciclosporin. ...
Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts ...
Hair Dyes and Aplastic Anemia. Drug and Chemical Toxicology, 1, 45-61. ... shunt in an ineligible liver transplant patient with primary biliary cirrhosis with refractory ascites and aplastic anemia ... A female showed a clinical spectrum of decreasing platelet count along with anemia due to oral ingestion of hair dye. It is ... Burnett, C.M., Corbett, J.F. and Lanman, B.M. (1977) Hair Dyes and Aplastic Anemia. Drug and Chemical Toxicology, 1, 45-61. ...
ICD 10 code for Refractory cytopenia with multilineage dysplasia and ring sideroblasts. Get free rules, notes, crosswalks, ... D46.2 Refractory anemia with excess of blasts [RAEB] D46.20 Refractory anemia with excess of blasts, unspecified ... D46.A Refractory cytopenia with multilineage dysplasia D46.B Refractory cytopenia with multilineage dysplasia and ring ... Refractory cytopenia with multilineage dysplasia and ring sideroblasts. 2016 2017 2018 2019 2020 2021 2022 2023 Billable/ ...
BMS Receives European Commission Approval for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma ... With Breyanzi, people in Europe living with relapsed or refractory DLBCL now have a differentiated CAR T cell therapy option ... and anemia (3%). Monitor complete blood counts prior to and after BREYANZI administration. ... In DLBCL, the most common form of non-Hodgkin lymphoma, up to 40% of patients have disease that is refractory to or relapses ...
Nandrolone decanoate for the treatment of erythropoietin refractory anemia: a case series. ComprTher. 2009;35(3-4):199-203. ... Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. Geriatr ...
Autoimmune hemolytic anemia (AIHA) is a heterogeneous disease mainly due to autoantibody-mediated destruction of erythrocytes ... chronic/refractory cases represent a challenge even for experts in the field. Bone marrow biopsy is fundamental to assess one ... Current and emerging treatment options for autoimmune hemolytic anemia Expert Rev Clin Immunol. 2018 Oct;14(10):857-872. doi: ... Autoimmune hemolytic anemia (AIHA) is a heterogeneous disease mainly due to autoantibody-mediated destruction of erythrocytes ...
Anaemia and intestinal parasitic infections among school age children in Behera Governorate, Egypt Behera Survey Team. Journal ... Treatment of patients with refractory giardiasis. Clinical infectious diseases, 2001, 33(1):22-8. ...
... relapsed or refractory mantle cell lymphoma; R/R MM, relapsed or refractory multiple myeloma. ... CRS is the most common side effect, including neutropenia, anemia and thrombocytopenia. CRS may be divided into four grades ... Early CD19-targeted CAR-T cell therapy was unsatisfactory in treating relapsed or refractory (R/R) B-ALL, as more than half of ... A total of 16 patients with relapsed/refractory lymphoma accepted infusion of 2G CAR-T cells (with CD28 only) and 3G CAR-T ...
Refractory anemia with excess of blasts 2 D46C Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality D470 ... Hereditary hemolytic anemia, unspecified D590 Drug-induced autoimmune hemolytic anemia D591 Other autoimmune hemolytic anemias ... D592 Drug-induced nonautoimmune hemolytic anemia D594 Other nonautoimmune hemolytic anemias D599 Acquired hemolytic anemia, ... Aplastic anemia, unspecified D62 Acute posthemorrhagic anemia D680 Von Willebrands disease D681 Hereditary factor XI ...
... refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with ...
The cases are presented because persistent chlamydial infection may contribute more frequently to chronic refractory anaemia ... Detection of Chlamydophila pneumoniae in the bone marrow of two patients with unexplained chronic anaemia. Nebe CT, Rother M, ... [email protected] Anaemia of chronic disease (ACD) is a common finding involving iron deficiency and signs ...
Chronic (unexplained) or refractory anemia. *Leukemia. *Lymphoma. *Multiple myeloma. *Neural tumors. *Pediatric leukemia, ...
The most common adverse reactions (≥20%) in patients with relapsed or refractory DLBCL treated with POLIVY in combination with ... BR are neutropenia, thrombocytopenia, anemia, peripheral neuropathy, fatigue, diarrhea, pyrexia, decreased appetite, and ... with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory DLBCL, ...
... relapsed or refractory multiple myeloma, hairy cell leukemia and anemia due to the effect of concomitantly administered ...
... refractory anemia with excess blasts, malignant immunoproliferative diseases ... refractory anemia with excess blasts. Expression (log2-scale):9.8779745. Number of Samples:23 Neoplasm. refractory anemia with ... neoplasms of lymphoid / hematopoietic and related tissue > myelodysplastic syndromes > refractory anemia with excess of blasts ...
  • Anemias with primary bone involvement include aplastic anemia and myelophthisic anemia . (medscape.com)
  • First-line treatment of severe aplastic anemia in patients ≥2yrs, in combination with standard immunosuppressive therapy. (empr.com)
  • Severe aplastic anemia in adults who have had insufficient response to immunosuppressive therapy. (empr.com)
  • They also influence the progression of hematologic diseases such as leukemia, multiple myeloma, and aplastic anemia, and may be a novel target when exploring treatments for related diseases in the future. (frontiersin.org)
  • No article was found for Anemia, Refractory, with Excess of Blasts and SETBP1[original query] . (cdc.gov)
  • Anemia is further broadly subcategorized into acute and chronic. (medscape.com)
  • For example, a gastrointestinal malignancy may cause anemia through blood loss, as well as lead to anemia of chronic disease. (medscape.com)
  • Go to Anemia and Pediatric Chronic Anemia for complete information on these topics. (medscape.com)
  • however, microcytic hypochromic indices also can be associated with anemia of chronic disease. (medscape.com)
  • Expert opinion: Although AIHA is considered benign and often easy to treat, chronic/refractory cases represent a challenge even for experts in the field. (nih.gov)
  • Treatment-refractory anaemia in a 35-year-old heart transplant recipient on chronic hemodialysis]. (bvsalud.org)
  • Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. (bvsalud.org)
  • liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. (yahoo.com)
  • With Breyanzi, people in Europe living with relapsed or refractory DLBCL now have a differentiated CAR T cell therapy option earlier in the treatment paradigm that provides long-term clinical benefit,' said Anne Kerber, senior vice president, head of Cell Therapy Development, Bristol Myers Squibb. (yahoo.com)
  • In DLBCL, the most common form of non-Hodgkin lymphoma, up to 40% of patients have disease that is refractory to or relapses following initial therapy. (yahoo.com)
  • in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least 2 prior therapies. (gene.com)
  • 11. Known significant glucose-6-phosphate dehydrogenase deficiency (favism, acute hemolytic anemia) (for systemic ozone therapy). (who.int)
  • Aniline may also cause the destruction of red blood cells, which manifests as acute or delayed hemolytic anemia. (cdc.gov)
  • Iron-refractory iron deficiency anemia results from an inadequate amount (deficiency) of iron in the bloodstream. (medlineplus.gov)
  • The symptoms of iron-refractory iron deficiency anemia can include tiredness (fatigue), weakness, pale skin, and other complications. (medlineplus.gov)
  • Although iron deficiency anemia is relatively common, the prevalence of the iron-refractory form of the disease is unknown. (medlineplus.gov)
  • Researchers suspect that iron-refractory iron deficiency anemia is underdiagnosed because affected individuals with very mild symptoms may never come to medical attention. (medlineplus.gov)
  • Mutations in the TMPRSS6 gene cause iron-refractory iron deficiency anemia. (medlineplus.gov)
  • Agnogenic myeloid metaplasia, which is characterized by anemia with primary bone marrow involvement, involves gradual bone marrow fibrosis, extramedullary hematopoiesis, and splenomegaly with no known underlying systemic disorder. (medscape.com)
  • This type of anemia includes sickle cell anemia, thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome, aortic valve prosthesis, disseminated intravascular coagulation (DIC), cold agglutinin disease, and paroxysmal cold hemoglobinuria (PCH). (medscape.com)
  • Autoimmune hemolytic anemia (AIHA) is a heterogeneous disease mainly due to autoantibody-mediated destruction of erythrocytes but also involves complement activation, dysregulation of cellular and innate immunity, and defective bone marrow compensatory response. (nih.gov)
  • Biological treatment is currently used as an alternative for the treatment of ulcerative colitis in patient's refractory to conventional treatment. (bvsalud.org)
  • Hematologic tests showed nonregenerative anemia (hemoglobin concentration 9 g/dL) and leukopenia (2.2 × 10 9 leukocytes/L) with profound lymphopenia (0.2 × 10 9 lymphocytes/L) and mild thrombocytopenia (135.0 × 10 9 platelets/L). A chest radiograph showed bilateral diffuse interstitial infiltrates. (cdc.gov)
  • Possible causes of macrocytic anemia include vitamin B-12 deficiency, folate deficiency, liver disease, and hypothyroidism. (medscape.com)
  • This slows the production of red blood cells and platelets, causing tiredness from anemia and a risk of bleeding from a low platelet count. (aamds.org)
  • In people with this form of anemia, red blood cells are abnormally small (microcytic) and pale (hypochromic). (medlineplus.gov)
  • The marrow does not respond appropriately to microcytic anemia, leading to decreased production of RBCs. (medscape.com)
  • In patients suffering from this condition, a key factor is the reduced bone vascularization with anemia and neutropenia often present, making them very susceptible to infections. (bvsalud.org)
  • Anemia is defined as an absolute reduction in the quantity of the oxygen-carrying pigment hemoglobin (Hgb) in the circulating blood. (medscape.com)
  • It is described as "iron-refractory" because the condition is totally resistant (refractory) to treatment with iron given orally and partially resistant to iron given in other ways, such as intravenously (by IV). (medlineplus.gov)
  • Chawla B, Iqbal FM, Chawla MS. Nandrolone decanoate for the treatment of erythropoietin refractory anemia: a case series. (veterinaria.org)
  • Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. (veterinaria.org)
  • To evaluate biological treatment in patients with ulcerative colitis refractory to conventional treatment in a 3rd level care Hospital. (bvsalud.org)
  • A descriptive, retrospective, longitudinal study was carried out in patients with UC who were refractory to conventional treatment and who received biological treatment. (bvsalud.org)
  • A wide array of diseases, including inflammations, infections, and malignancies, may at some point be associated with anemia. (medscape.com)
  • A female showed a clinical spectrum of decreasing platelet count along with anemia due to oral ingestion of hair dye. (scirp.org)
  • After a few years, the patient returned with refractory infectious, demonstrating on clinical examination, submandibular fistula with spontaneous drainage and reconstruction plate externalization in parasymphysis region of previous surgery. (bvsalud.org)
  • Anemia is a manifestation of an underlying disease process and is not a diagnosis in itself. (medscape.com)
  • A disease may lead to anemia through a combination of mechanisms. (medscape.com)
  • Normocytic anemia is further divided into 2 broad categories: anemia with primary bone marrow involvement and anemia secondary to underlying disease. (medscape.com)
  • Most cases of anemia in the world are secondary to an underlying disease. (medscape.com)
  • The true incidence of anemia is difficult to define because of multiple factors (eg, patient population, geographic location, normal range reference, ability to adequately screen for the disease). (medscape.com)
  • The abnormal cells cannot carry oxygen effectively to the body's cells and tissues, which leads to fatigue, weakness, and other symptoms of anemia . (medlineplus.gov)
  • For patient education information, see Anemia . (medscape.com)
  • Anemia usually is grouped into 3 etiologic categories: decreased red blood cell (RBC) production, increased RBC destruction, and blood loss. (medscape.com)
  • Anemia is far more common in underdeveloped countries than in the United States. (medscape.com)
  • Some published studies report the incidence of anemia to be 2-15% in the United States and Great Britain. (medscape.com)
  • On day 10, the lymphocyte level had returned to reference range and the anemia had become regenerative. (cdc.gov)
  • The etiology of myelophthisic anemia involves interruption of normal hematopoiesis due to the accumulation of malignant or reactive cells or cell products. (medscape.com)